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ABSTRACT 
Canine and feline hyperlipidemia is associated with various diseases and can cause 
clinically relevant complications, such as cutaneous xanthomas, hepatobiliary diseases (e.g., 
cholelithiasis, cholestasis, vacuolar hepatopathy, snf bilisty mucocele), pancreatitis, glomerular 
disease, lipemia retinalis, or peripheral neuropathy. However, dyslipidemia has not been 
extensively investigated in dogs and cats, maybe in part because dogs and cats are high-density 
lipoprotein (HDL) predominant species and the development of atherosclerosis is rare. This 
study aimed to evaluate the lipoprotein profile by continuous lipoprotein density profiling 
(CLPDP) method in dogs and cats with various gastrointestinal (GI) diseases, including exocrine 
pancreatic insufficiency (EPI), chronic enteropathy (e.g., idiopathic inflammatory bowel 
disease), and hepatic diseases. The CLPDP is a novel density gradient ultracentrifugation (DGU) 
technique, which uses a self-generating density gradient solution, bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA), and a fluorescent probe, N-[7-(4-nitrobenzo-2-
oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-sphingosine (NBD C6-ceramide). We performed 
the partial validation assay of the CLPDP assay for use with canine serum samples. The intra- 
and inter- assay variability showed that the CLPDP was precise and reproducible for nominal 
low-density lipoprotein (LDL)/HDL and HDL, whereas the method was precise but not 
reproducible for TRL.  
Our study showed that patients with GI diseases that lead to malassimilation (i.e., 
exocrine pancreatic insufficiency [EPI] and chronic enteropathies) most likely have decreased 
serum lipid concentrations consisting of LDL and high-density lipoproteins HDL compared to 
healthy control animals. Cats with hepatic lipidosis had divergent lipoprotein profiles compared 
to healthy control cats. The amounts of lipid within the density of 1.0374-1.0438 g/mL 
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distinguished healthy control cats from cats with HL with a sensitivity of 87% and a specificity 
of 90%. Dogs with liver disease (i.e., chronic hepatitis: CH or portosystemic shunt:PSS) had 
significantly different lipoprotein profiles compared to healthy control dogs. Dogs with PSS had 
significantly decreased levels of lipoprotein fractions compared to dogs with CH and healthy 
control dogs. These findings could potentially have diagnostic and prognostic implications in 
dogs and cats with GI disease. In addition, lipoprotein profiles may aid in the better 
understanding of the role of lipid metabolism in GI diseases and may even aid in the 
development of novel therapeutic approaches.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
I.1 Lipoprotein structure and classification  
Lipoproteins are conglomerates of lipid and protein. The main function of lipoproteins is 
to transport water-immiscible lipids in the aqueous environment of the blood and across cell 
membranes.1 Lipoproteins form a micelle-like structure as they have a hydrophilic exterior and a 
hydrophobic core.2 Particularly, because triacylglycerol and cholesterol esters are hydrophobic, 
they have to be coated with amphipathic compounds: phospholipids, unesterified cholesterol, and 
proteins. The polar heads of the phospholipid and the free hydroxyl group of cholesterol are 
aligned towards the external polar environment in the blood stream. Triacylglycerol and 
cholesterol esters are stabilized in the core.  
The density of the particle is influenced by the composition of lipids and proteins within 
the particle.3 As density increases, the ratio of triacylglycerol to phospholipids and cholesterol 
decreases. In addition, there is a strong relationship between biological function and the density 
class. Thus, in humans, lipoproteins are commonly categorized into 5 classes based on their 
densities: chylomicrons, very low density lipoprotein (VLDL), intermediate-density lipoprotein 
(IDL), low density lipoprotein (LDL), and high density lipoprotein (HDL). The term IDL is often 
used interchangeably with remnant particles. IDL has not been characterized in dogs and cats.1 It 
is important to note that lipoproteins within a same class are not homogenous, rather they are 
metabolic continuums. There is a wide variety of particle sizes and chemical compositions within 
each class, and there is an overlap between them.3  
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I.2 Lipoprotein functions  
As mentioned above, the density classes of lipoproteins are well associated with their 
biological functions. Chylomicrons are the largest particles and their main functions are to 
transport dietary triglycerides (TG) from the small intestine to adipose tissue and skeletal/cardiac 
muscle as well as to transport dietary cholesterol to the liver.4 Fat-soluble vitamins, vitamin A, 
D, E, and K, are also incorporated into chylomicrons.5 The chylomicron remnants are taken up 
by the liver and some vitamin components are stored in the lipocytes of the liver. Chylomicrons 
are the most abundant lipoproteins in the blood circulation for a few hours after the ingestion of a 
meal.6 The other classes of lipoproteins are considered to be the endogenous lipoproteins.1 
VLDL are secreted from the liver in order to export endogenously synthesized triglycerides and 
deliver triglycerides to adipose and muscle tissues. VLDL lose triacylglycerol and 
apolipoproteins and become a smaller and denser particles, LDL, which mainly transport 
cholesterol to peripheral tissues and liver. HDL serve to remove cholesterol from peripheral cells 
and macrophages to the liver. This “reverse cholesterol transport” process is considered 
antiatherogenic in humans. 
I.3 Lipoprotein metabolism  
Lipoprotein metabolism is quite complex. Dominiczak et al. introduced three conceptual 
frameworks: the fuel transport pathway (metabolism of chylomicrons, VLDL, and remnant 
particles), the overflow pathway (metabolism of LDL), and the reverse cholesterol transport 
(metabolism of HDL).4 This approach should aid in better understanding of the pathogenesis of 
lipid disorders and relevant therapeutic interventions.  
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I.3.1 Fuel transport pathway  
The fuel transport pathway delivers TG to peripheral tissues by chylomicrons and VLDL. 
Dietary TG are incorporated into chylomicrons in the enterocytes and secreted into the lymph 
within intestinal lacteals. In peripheral tissues, TG within chylomicron are hydrolyzed into free 
fatty acids and glycerol by lipoprotein lipase (LPL) from the vascular endothelium. After losing 
TG, chylomicrons decrease in size and become chylomicron remnants. The remnants bind to the 
LDL receptor related protein (LRP) and LDL receptor and are internalized into hepatocytes. In 
contrast to the absorption of dietary TG, endogenously synthesized TG are secreted within 
VLDL particles from the liver. TG within VLDL are partially hydrolyzed by LPL. VLDL 
particles then decrease in size and become VLDL remnants. VLDL remnants are taken up by the 
liver via the LDL receptors. It is important to note that VLDL remnants exchange some TG with 
cholesterol ester within HDL in a process mediated by the cholesteryl ester transfer protein 
(CETP).  
I.3.2 Overflow pathway  
While VLDL remnants are taken up by the liver, further lipolysis occurs by hepatic 
triglyceride lipase (HTGL) from endothelium in the hepatic microvasculature. During this 
process, the remnants lose apolipoprotein C and E, decrease in size, and become LDL. More 
LDL particles are generated when the remnant supply from the fuel transport pathway is 
excessive. LDL is also taken up by binding to the LDL receptor in the liver. Their cellular uptake 
increases when LDL receptor expression increases because of a decrease in intracellular 
cholesterol concentration.  
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I.3.3 Reverse cholesterol transport and cholesterol recycling  
HDL is assembled on the matrix of the apolipoprotein AI (apoAI).4 ApoAI is secreted 
from the liver and intestine. It has been suggested that apoAI binds to phospholipid molecules as 
it leaves the cell and become pre-β1 HDL. Pre-β1 HDL acquires phospholipids and free 
cholesterol by interactions with peripheral cell membranes and become discoidal HDL. Discoidal 
HDL acquires more cholesterol by binding to the membrane ATP-binding cassette transporter 
A1 (ABCA1) that controls an efflux of free cholesterol from cells4. Cholesterol is subsequently 
esterified by lecithin-cholesterol acyltrasferase (LCAT). Discoidal HDL acquires phospholipids 
and free cholesterol from TRL via phospholipid transfer protein (PLTP). Accumulation of 
cholesterol esters leads to discoidal HDL becoming smaller spherical particles, called HDL3. 
Furthermore, by transferring cholesteryl esters to TRL in exchange for TG, HDL3 turns into 
larger particles, which are HDL2. Cholesterol esters within HDL2 are taken up by the scavenger 
receptor B1 in the liver. By losing cholesterol esters, HDL2 becomes lipid-poor apoAI, which is 
a precursor for HDL.  
I.4 Clinical significance of lipoprotein profiling in human medicine  
Epidemiological studies have shown that altered proportions of lipoproteins is associated 
with an increased risk of cardiovascular disease.7 More specifically, elevated LDL-cholesterol 
and/or decreased HDL-cholesterol are associated with an increased risk of atherosclerotic 
cardiovascular disease (ASCVD).7,8 The subendothelial retention of apolipoprotein B-containing 
lipoproteins has been thought to initiate the process of atherogenesis.9 These retained 
lipoproteins promote a chronic and maladaptive macrophage-and T-cell-dominant inflammatory 
response, leading to a subsequent development of lesions.10 Even though the etiology of ASCVD 
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is multifactorial, LDL-C has been widely used for cardiovascular risk assessment.11 In addition, 
HDL is thought to have a protective effect on ASCVD because of its capacity to remove 
cholesterol and also its anti-inflammatory properties.12 However, it has been controversial 
whether lowering LDL and/or raising HDL reduce the risk of ASCVD.11,13,14 Several studies 
have shown that lipoprotein profiles as well as plasma cholesterol and triglyceride concentrations 
can be altered in human patients with inflammatory conditions.15-17 In turn, chronic inflammatory 
disorders, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and inflammatory 
bowel disease (IBD) are associated with an increased risk of atherosclerotic cardiovascular 
disease in humans.17 
I.5 Clinical significance of lipoprotein profiling in veterinary medicine  
Hyperlipidemia is defined as an increased concentration of plasma triglycerides and/or 
cholesterol, and can due to excessive production and/or delayed degradation of lipoprotein. 
Hyperlipidemia is generally associated with various diseases and can cause clinically relevant 
complications, such as cutaneous xanthomas,18 liver disease,19 cholelithiasis,20 pancreatitis,21 
glomerular disease,22 lipemia retinalis, or peripheral neuropathy.23 Moreover, altered lipid profiles 
have been reported in dogs with obesity,24,25 hyperadrenocorticism,26 dominance aggression,27 
lymphoma,28 and some infectious diseases.29,30 The causes of hyperlipidemia in dogs are either 
primary or secondary to other diseases. Secondary hyperlipidemia is the most common form and 
several diseases, such as hypothyroidism, diabetes mellitus, or pancreatitis, have been associated 
with the development of secondary hyperlipidemia. Primary hyperlipidemia is also often 
associated with certain breeds, such as Miniature Schnauzers or Shetland Sheepdogs.21,31-33 On the 
other hand, idiopathic hyperchylomicronemia18,34 and idiopathic hypercholesterolemia have been 
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reported in cats. Ginzinger et al. showed that cats with autosomal recessive defect in lipoprotein 
lipase activity had primary hyperlipidemia.34 The clinical usefulness of measurement of the plasma 
cholesterol concentration in dogs and cats is minimal because it is not associated with development 
of complications as is the case in humans. On the other hand, hypertriglyceridemia has been 
reported to be a risk factor for pancreatitis in Miniature Schnauzer,35 hepatobiliary disease (e.g., 
cholelithiasis, cholestasis, vacuolar hepatopathy, snf bilisty mucocele),36 atherosclerosis,37 and 
ocular disease, 38,39 seizures and other neurologic signs.40,41  
I.6 Assessment of biological functions of lipoproteins  
To assess lipoproteins qualitatively or quantitatively, the lipid contents of each 
lipoprotein subclass (e.g., LDL-Cholesterol) and the concentrations of apolipoproteins 
(apoB48/B100/AI) are often evaluated. On the other hand, to assess the biological function of 
lipoproteins, several characteristics of lipoprotein properties can be analyzed. For example, 
measurement of the lecithin:cholesterol acyltransferase (LCAT) activity, HDL cholesterol efflux 
capacity, and HDL antioxidant capacity represent the biological function of lipoproteins. It is 
also important to note that in human medical settings, plasma/serum triglyceride and cholesterol 
concentrations as well as LDL-cholesterol (LDL-C) and HLD-cholesterol (HDL-C) are 
commonly measured. 
I.7 Methodology for lipoprotein profiling 
As mentioned above, in human medicine, the standard method to assess LDL and HDL 
levels in clinical practice is to quantify the cholesterol content of LDL and HDL particles by the 
Friedewald equation. This is an effective diagnostic test because delayed LDL clearance results 
in increased plasma LDL-C as well as increasing the modifications of LDL particles42 that make 
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them atherogenic.43-46 However, lipoproteins are highly heterogeneous particles, and cholesterol 
concentrations within the lipoprotein particles do not necessarily reflect their biological 
properties.47 In fact, although it has been well recognized that increased plasma LDL-cholesterol 
concentrations are associated with an increased risk for cardiovascular disease (CVD), a 
relatively high proportion of patients with CVD have plasma LDL-C concentrations within the 
reference interval.48 Other methodologies have been introduced to assess the lipoprotein profile, 
including density gradient ultracentrifugation DGU), proton nuclear magnetic resonance (NMR), 
vertical auto profile (VAP), high performance liquid chromatography (HPLC).  
I.7.1 Friedewald method  
The standard method for assessing LDL level in clinical patients is to calculate the 
estimated cholesterol content in LDL particles by the Friedewald equation (LDL-C= total 
cholesterol – HDL-C – triglycerides/5) after precipitation of apoB-containing particles.49 In fact, 
even though epidemiological studies have shown a consistent inverse association between HDL-
C and cardio vascular disease (Boekholdt et al., 2013), clinical trials have shown that raising 
HDL-C pharmacologically does not reduce the incidence of CAD (Schaefer, 2013; Hafiane and 
Genest, 2015b). This finding might suggest that HDL-C is not directly responsible for the 
development of CAD, but rather something correlated with it. In other words, cholesterol 
concentrations within HDL might not represent antiatherogenic properties of HDL. Therefore, it 
would be more meaningful to evaluate overall lipoprotein distributions rather than cholesterol 
concentrations within lipoprotein particles (Larner et al., 2011; Hafiane and Genest, 2015a).  
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I.7.2 Density gradient ultracentrifugation  
Density gradient ultracentrifugation (DGU), including rate zonal ultracentrifugation and 
isopycnic ultracentrifugation, has been the gold standard to separate and identify lipoproteins 
based on their density (Chapman et al., 1981). Typical DGU protocols are often very time-
consuming because they require sequential centrifugation steps, and cannot capture the 
continuous density distribution of lipoproteins. In addition, lipid content (i.e., cholesterol and 
triglyceride concentrations) is usually measured by enzymatic assays following the 
ultracentrifugation isolation steps.  
I.7.3 Nuclear magnetic resonance spectroscopy  
Proton nuclear magnetic resonance (NMR) spectroscopy can measure lipoprotein particle 
numbers and sizes instead of the cholesterol content of LDL and HDL.50 Each lipoprotein 
subclass has a different size and emits distinctive NMR signal and the signal amplitude measured 
for each subclass is directly proportional to the number of subclass particles emitting the signal. 
Lipoprotein sizes and particle numbers provide additional clinically useful information about the 
lipid profile for a specific individual because patients with same LDL-C concentrations can have 
significantly different numbers and sizes of LDL particles and a different risk for cardiovascular 
diseases.50 Jeyarajah et al. showed a strong correlation between chemically measured and NMR 
measured triglycerides (r = 0.978) and HDL-C (r = 0.959) concentrations in human plasma 
samples.50 Mora et al. showed that cardiovascular disease risk prediction evaluated by 
lipoprotein size and numbers measured by NMR was comparable but not superior to that of 
standard measurements of lipids and apolipoproteins in the prospective study of healthy 
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women.51 Further studies are warranted to investigate the clinical utility of NMR spectroscopy 
for the evaluation of lipoproteins.  
I.7.4 Vertical auto profile  
The vertical auto profile (VAP) is an inverted rate zonal, single vertical spin, density 
gradient ultracentrifugation technique that simultaneously measures cholesterol concentrations of 
five lipoproteins classes and their subclasses.52 The VAP method uses a vertical rotor and 
separates lipoproteins across the shorter horizontal axis of the centrifuge tube, which allows 
separating all lipoproteins in less than 1 hour. After centrifugation, the contents are drained from 
the bottom of the tube by puncturing it with a needle, and are slowly and continuously mixed 
with a flowing enzymatic reagent. As the mixture flows through the tube, the absorbance 
corresponding to the intensity of the red color is monitored with a spectrophotometer at 505 
nm.52,53  
I.7.5 High performance liquid chromatography  
High performance liquid chromatography (HPLC) has been widely used for the 
separation and analysis of many substances. There are three types of HPLC columns for 
biological samples: reversed-phase (RPHPLC), ion-exchange (HPIEC), gel-permeation 
(HPGPC) or size-exclusion (HPSEC) columns.54 HPGPC is recommended for separation of 
serum lipoproteins because they are large spherical particles with lipid core and hydrophilic 
outer layer, and the size of different classes of lipoprotein sizes differ remarkably, which allows 
separation through an HPGPC column.54 The amount of each lipoprotein class can be quantified 
by calculating the area under the curve. In contrast, RPHPLC and HPGPC are usually used for 
analysis of apolipoproteins.54 The advantages of HPLC for serum lipoprotein analysis include 
 10 
 
shorter processing and analysis time, high resolution and reproducibility, and a small sample 
volume.54  
I.7.6 Gel electrophoresis  
Several types of gel electrophoresis have been used to determine lipoprotein profiles, but 
it is important to note that different types of gel electrophoresis serve a different purpose for 
lipoprotein analysis. Agarose gel electrophoresis is used to classify lipoproteins by the 
nomenclature beta, pre-beta, and alpha based on the mobility of LDL, VLDL, and HDL, 
respectively.55 Non-denaturing polyacrylamide gradient gel electrophoresis (ND-PAGGE) has 
been used to separate lipoprotein subclasses based on their diameter size. Two-dimensional 
gradient gel electrophoresis (2D-PAGGE) uses the surface charge and particle size of 
lipoproteins to separate lipoprotein subclasses.  
I.7.7 Measurements of apolipoproteins  
Apolipoproteins are proteins within lipoprotein particles. The main functions of 
apolipoproteins include providing structural components for assembly of lipoprotein particles, 
and regulating lipoprotein metabolism.4,5 ApolipoproteinB100 (apoB100) is synthesized in 
hepatocytes and its main function is to serve as a structural component of VLDL and LDL as 
well as serving as a ligand for LDL-receptors for uptake by the liver. One molecule of apoB 
resides per lipoprotein particle. Thus, it is a marker of the number of lipoprotein particles.4 
Apolipoprotein B48 (apoB48) is a structural component of chylomicrons. ApoB48 and apoB100 
are transcribed from a single gene. Since one molecule of apoB48 is present in each chylomicron 
particle, it serves as a marker of the number of chylomicrons and their remnants. 
ApolipoproteinAI (apoAI) constitutes 70% of HDL apolipoproteins. It activates LCAT and 
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possesses anti-inflammatory and antioxidant properties. Serum concentration of apoAI is the 
most important marker of the activity of reverse cholesterol transport. Measurements of the 
concentrations of apoAI and apoB are carried out by immunological methods using antibodies 
raised against specific epitopes. Current techniques include enzyme-linked immunosorbent 
assays (ELISA), immunonephelometry, and imunoturbidimetry.4 
I.7.8 Continuous lipoprotein density profiling  
As mentioned above, typical DGU techniques are often very time-consuming because 
they require sequential centrifugation steps. Continuous lipoprotein density profiling (CLPDP) is 
a novel DGU technique, which uses a self-generating density gradient solution, bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA), and a fluorescent probe, NBD C6-ceramide.56 The 
advantages of this technique are that it requires only one ultracentrifugation step, lasting 6 hours, 
and allows the investigator to visualize a continuous distribution of lipoproteins (lipoprotein 
profile) and to estimate the concentrations of lipoprotein subfractions by calculating the area 
under the curve. Henriquez et al. reported that CLPDP was able to distinguish between a control 
group and a cardiovascular disease group without assessing the traditional risk factors, elevated 
levels of LDL-C and/or decreased levels of HDL-C.2 Xenoulis et al. investigated the usefulness 
of the CLPDP in canine serum and reported lipoprotein profiles in healthy dogs of various 
breeds, healthy miniature schnauzers, and miniature schnauzers with hyperlipidemia.56 
I.8 Lipodomic changes in human IBD patients and in canine and feline patients with chronic 
gastrointestinal disease 
Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders 
characterized by persistent or recurrent GI signs and histologic evidence of intestinal 
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inflammation in the absence of an identifiable trigger or infection.57 There are two major forms 
of IBD in humans: ulcerative colitis (UC) and Crohn’s disease (CD).58 The difference between 
UC and CD is mostly based on the distribution of affected sites. UC is a severe ulcerating 
inflammatory disease that is limited to the colon and rectum affecting the mucosa and 
submucosa. In contrast, CD may involve any area of the GI tract, frequently involving the ileum, 
and is typically transmural.59 IBD in humans is clinically and histologically different from IBD 
in cats and dogs even though the etiology might be similar.57 Intestinal inflammation is thought 
to be caused by a complex interaction between genetic, environmental and microbial factors, and 
the immune system.60 However, the etiology of IBD remains largely unknown. 57 It has been 
previously recognized that IBD is associated with dyslipidemia. Lipid profile in a clinical setting 
in human medicine mostly include total plasma cholesterol, low-density lipoproteins cholesterol 
(LDL-C), and high-density lipoproteins cholesterol (HDL-C). IBD is associated with lower 
levels of total cholesterol and LDL-C, and either increased or unchanged levels of triglyceride 
and HDL-C.15,61 Metabolomic studies have reported a number of disrupted metabolic pathways 
in IBD patients.62 Using a lipidomics approach, it has been revealed that lipid metabolism, 
mainly sphingomyelin (SM) and ceramide metabolism, are significantly altered in an 
experimental IBD mouse model.63 Moreover, lipid metabolism and its signaling are suggested to 
play important roles in the pathogenesis of IBD.64  
I.8.1 Phospholipids  
I.8.1.1 Glycerophospholipid  
Three classes of membrane lipids, glycerolipids, sphingolipids and steroids, are widely 
distributed throughout the body.5 Of these, glycerolipids are quantitatively by far the most 
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important group of membrane lipids. They can be divided into two main groups: those 
containing phosphorus (phosphoglycerides) and those without phosphorus but containing a sugar 
moiety (glycosylglycerides), both of which are based on a glycerol backbone.5 
Phosphoglycerides dominate in higher animals, whereas glycosylglycerides are more important 
in plants. Recently, Fan et al. investigated the relationship between the individual molecular 
species of lipids and human IBD.64 They analyzed lipid profiles consisting of 333 lipid species in 
plasma of IBD patients (UC: n=16 and CD: n=24) and healthy volunteers (n=84). Plasma total 
cholesterol and LDL-C concentrations of patients with CD were lower than the ones in patients 
with UC. The lipidomic profiles were profoundly different in patients with CD but not with UC 
when compared with healthy controls. Most importantly, a number of ether lipids (i.e., 
alkylphospholipids and alkenylphospholipids (a.k.a., plasmalogens)) was negatively associated 
with CD, but not with UC. It has been known that the vinyl ether linkage of plasmalogens is 
particularly susceptible to oxidation by reactive oxygen species (ROS).65 Therefore, 
plasmalogens serve as antioxidants and protect other lipids in lipoproteins and membranes 
against oxidation. The decrease of plasmalogens may lead to impaired antioxidant defense, thus 
contributing to the pathology of IBD.64 The differences in lipidomic profiles between patients 
with CD and those with UC may be due to the fact that CD affects larger areas of the intestinal 
tract. Thus, lipidomic profiling might serve as a potential diagnostic modality for evaluating 
disease severity. Lower levels of plasmalogens in patients with CD may be due to enhanced 
oxidative decomposition of plasmalogens because an increase in oxidative stress is associated 
with IBD. In contrast, the fact that there is no significant decrease in plasmalogens in UC 
patients may be due to less intestinal area being affected in patients with this condition.  
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I.8.1.2 Sphingolipids  
Sphingolipids contain a sphingosine or ceramide rather than a glycerol as a backbone.5,66 
Sphingolipids are widespread in membranes but are particularly abundant in nervous tissue. In 
addition, they are concentrated in the outer layer of the plasma membrane. Recent studies have 
shown that sphingolipids play a role in modulating various cellular events including 
proliferation, differentiation, apoptosis, and inflammation.66 Two sphingolipid classes, the 
ceramide precursor dihydroceramide and the ceramide metabolite trihexosylceramide as well as 
11 sphingolipid species, including 4 sphingomyelin species in plasma were found to be 
negatively associated with human IBD, suggesting a possible dysregulation of sphingolipid 
metabolism in human IBD patients.64 Sewell et al. quantified the concentrations of individual 
ceramide and dihydroceramide species, sphingoid bases, and total ceramide content in 
macrophages from healthy subjects (n=7) and patients with CD (n=8).67 Sphingolipid 
composition of macrophages is altered after stimulation with E. coli but did not differ between 
macrophages isolated from HC or CD patients.  
I.8.2 Fatty acids and sterols  
It has been suggested that fatty acid metabolism is involved in the immune response and 
inflammatory processes in human IBD patients. Esteve-Comas et al. described an abnormal 
polyunsaturated fatty acids (PUFA) pattern, consisting of increased levels of α-linoleic acid 
(C18:3n3) and docosahexaenoic acids (DHA, C22;6n3) and decreased level of dihommo-γ-
linoleic (C20:3n6), in patients with active IBD.68 In their study, even in patients with severe 
disease, plasma concentrations of the n3-PUFA remained higher than those in healthy controls.68 
These findings suggest that the synthesis of PUFA might be enhanced in patients with active 
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IBD and that the utilization of n6 PUFA might be increased due to increased demands for 
biosynthesis of eicosanoids. In order to examine this hypothesis, the same investigators later 
compared plasma fatty acid concentrations between patients with inactive IBD (n=24, UC 
without colectomy; n=15, UC with colectomy; n=27, CD) and healthy controls (n=107). Plasma 
concentrations and percentage of DHA was significantly higher in patients with inactive UC and 
CD than in controls. Arachidonic acid (C20:4n6), the main fatty acid of the n6 series, showed the 
same tendency, but the difference did not reach statistical significance. These results indicate that 
in patients with active IBD, the biosynthesis of PUFA (both n3 and n6) as well as the utilization 
of n6 PUFA for production of eicosanoids are enhanced, while in inactive IBD cases, 
concentrations of n6-PUFAs are even higher compared to healthy controls because the utilization 
of n6-PUFA is decreased due to a decrease in disease activitity. These investigators also pointed 
out that these results brought up a concerning potential negative effect of the use of long chain 
n3-PUFA in treatment for either acute attacks of IBD or for maintenance treatment of the 
disease.  
In veterinary medicine, there are several studies that evaluated lipoprotein profiles using 
traditional methods, including the measurement of plasma total cholesterol, LDL-C, HDL-C. 
However, limited published reports regarding lipidomics are available. Honneffer et al. evaluated 
both sterol and fatty acid concentrations in healthy control dogs and dogs with EPI undergoing 
enzyme supplementation.69 Their study showed that concentrations of all fecal fatty acids were 
significantly increased in dogs with EPI. The fatty acids evaluated in this study included 
essential fatty acids, such as linoleic acid and α-linoleic acid, and other unsaturated fatty acids, 
such as exhisonic acid, erucic acid, gondoic acid, and oleic acid. Among sterols, cholesterol 
concentrations did not significantly differ between both groups, while coprostanol was decreased 
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along with several phytosterols (i.e., sitosterol, campesterol, fucosterol, sitostanol, and 
stigmasterol).69 This study suggested that fat assimilation does not normalize completely with 
enzyme supplementation even when clinical signs of EPI are well-managed.  
The effect of cholestyramine on lipid metabolism was studied by measuring fecal fatty 
acids and sterol concentrations in healthy dogs before and after administration of 
cholestyramine.70 Cholestyramine forms insoluble complexes with bile acids, preventing 
intestinal reabsorption of bile acids and thus enhancing their fecal elimination. As expected, the 
concentrations of all measured sterols were significantly decreased after administration of 
cholestyramine, including phytosterols (i.e., sitostanol, campesterol, sitosterol, stigmasterol, 
fucosterol) and zoosterols (i.e., cholesterol, coprostanol, and cholestanol). Several fecal fatty acid 
concentrations increased after administration of cholestyramine (i.e., oleic acid, stearic acid, and 
palmitic acid), while only linolenic acid decreased significantly. This result suggests that 
cholestyramine may have a significant effect on intra-luminal homeostasis of sterols and 
assimilation of fatty acids.  
I.8.3 Total cholesterol, LDL-C, and HDL-C  
In humans, IBD patients exhibit lower plasma concentrations of LDL-C and total 
cholesterol compared to healthy subjects. These differences are more profound in CD patients 
than UC patients. In addition, HDL-C and TG concentrations do not differ between IBD patients 
and healthy subjects.61 These findings remain consistent independently of disease activity and 
are also observed post-operatively.71 Even though the pathogenetic mechanism causing these 
alternations have not been fully elucidated, lipid metabolism has emerged as an important 
mediator for the development of inflammatory diseases, including IBD. Several pathways of the 
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mechanism of alternations of lipid metabolism have been revealed. During the early stages of 
inflammation, serum concentrations of VLDL and TG are increased. It has been suggested that 
the effects of infection and inflammation on TG metabolism are similar in all species, while 
changes in cholesterol metabolism differ between rodents and primates.72 In rodents, serum total 
cholesterol concentrations and hepatic cholesterol synthesis are increased; on the other hand, 
humans and nonhuman primates have either no changes or show a decrease in serum cholesterol 
and low-density lipoproteins (LDL). Consequently, inflammatory conditions lead to alternations 
in the composition and function of lipoproteins, including changes in sphingolipid 
concentrations, decreased reverse cholesterol transport, and increased oxidation of lipids. As a 
result, high-density lipoproteins (HDL) concentrations are decreased in these patients.72 
I.9 Hypotheses and specific objectives  
I.9.1 Hypotheses 
The hypotheses of this study are 1) that the CLPDP would be a useful tool for the 
assessment of lipoprotein profiles in dogs and cats and 2) that dogs and cats with gastrointestinal 
disease or chronic enteropathy and hepatic diseases have altered lipoprotein profiles measured by 
CLPDP when compared to healthy controls.  
I.9.2 Specific objectives  
The objectives to prove or disapprove these hypotheses were: 1) to perform partial inter- 
and intra-assay validation of the CLPDP with use of canine serum samples; 2) to evaluate the 
effects of freeze-thaw cycles of canine serum samples on the results of CLPDP; 3) to perform 
short- and long- term stability studies on canine serum samples kept under different storage 
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conditions; and 4) to evaluate lipoprotein profiles in dogs and cats with various gastrointestinal 
diseases.  
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CHAPTER II  
ANALYTICAL ASSESSMENT OF CONTINUOUS DENSITY GRADIENT 
ULTRACENTRIFUGATION PROFILING METHOD FOR USE WITH CANINE SERUM  
II.1 Introduction  
In humans, the standard method for assessing LDL level in clinical practice is to quantify 
plasma LDL-C concentration by calculating estimated cholesterol contents in LDL particles by 
the Friedewald equation (LDL-C= total cholesterol – HDL-C – triglycerides/5).49 This is an 
effective diagnostic test because delayed LDL clearance results in increased plasma LDL-C as 
well as increasing the modifications of LDL particles42 that make them atherogenic.43-46 
However, lipoproteins are highly heterogeneous particles, and cholesterol concentrations within 
the lipoprotein particles do not necessarily reflect their biological properties.73 Therefore, it could 
be more meaningful to evaluate entire lipoprotein distributions rather than cholesterol 
concentrations within lipoprotein particles.73,74  
Density gradient ultracentrifugation (DGU), including rate zonal ultracentrifugation and 
isopycnic ultracentrifugation, has been the gold standard for separating and identifying 
lipoproteins based on their density.75 Typical DGU techniques are often very time-consuming 
because they require sequential centrifugation steps. Continuous lipoprotein density profiling 
(CLPDP) is a novel DGU technique, which uses a self-generating density gradient solution, 
bismuth sodium ethylenediaminetetraacetic acid (NaBiEDTA), and a fluorescent probe, NBD 
C6-ceramide (N-[7-(4-nitrobenzo-2-oxa-1,3-diazole)]-6-aminocaproyl-D-erythro-
sphingosine).56,74 The advantages of this technique are that it requires only one 
ultracentrifugation, lasting 6 hours, and allows visualization of a continuous distribution of 
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lipoproteins (lipoprotein profile) and also quantification of lipoprotein subfractions by 
calculating the area under the curve (AUC). The CLPDP was initially developed to analyze 
human lipoprotein profiles but was used in other species as well.56,76,77 A recent study used this 
technique to analyze canine lipoprotein profiles in healthy dogs.56 However, this technique has 
not been analytically validated in canine serum samples, and the stability of lipoproteins for use 
with canine serum and the effect of freeze-thaw cycles with different storage conditions on 
lipoprotein profiles in canine serum have not been investigated.  
It is important to note that HDL is the predominant lipoprotein in dogs, whereas in 
humans, LDL predominates.1 In addition, there is overlap in the density distributions of canine 
LDL and HDL particles, making it impossible to separate LDL and HDL completely by density 
centrifugation alone.78,79 Thus, the density distribution of human lipoproteins cannot be simply 
applied to canine lipoprotein classification. The diameters of LDL and HDL lipoproteins in 
humans and dogs have been reported previously.80 One way to evaluate the application of the 
CLPDP in canine samples would be to measure diameters of canine lipoproteins in two ranges, 
corresponding to human LDL and HDL. Observing the distribution of lipoprotein sizes in 
lipoprotein profiling by the CLPDP would help us better understand how this technique separates 
canine lipoproteins. The aims of this study were 1) to partially validate the CLPDP technique for 
lipoprotein profiling in canine serum, 2) to assess the stability of lipoproteins in canine serum 
samples under different storage conditions, 3) to assess the freeze-thaw cycle effects on 
lipoprotein profiling in canine serum, and 4) to investigate the shapes and sizes of both canine 
and feline lipoprotein particles using electron microscopy.  
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II.2 Materials and methods  
II.2.1 Nomenclature  
For the purpose of assay validation, stability assessment, and electron microscopic 
analysis, fractional lipoprotein intensities of TRL (1.0102-1.0190 g/mL), nominal LDL/HDL, 
(1.0191-1.0629 g/mL), and nominal HDL (1.0632-1.1781 g/mL) were determined by measuring 
the area under the curve (AUC) of the each density range. AUC% for the 3 density regions were 
calculated by normalizing by a total AUC (AUC for each density range/a total AUC=AUC%).  
II.2.2 Assay repeatability and reproducibility  
Partial validation test was performed for assay repeatability and reproducibility. Surplus 
serum samples submitted to the Gastrointestinal Laboratory (GI Lab) at Texas A&M University 
were pooled and aliquoted for determination of both intra-(repeatability)and inter- 
(reproducibility) assay validation. The intra-assay validation was performed at the same day. The 
rest of aliquots were kept at -80°C and inter-assay validation was performed within 3 months. 
Both AUC and %AUC were calculated for TRL, nominal LDL/HDL, and nominal HDL. 
Repeatability was determined by calculating the intra-assay coefficient of variation (%CV) of 
each density region (TRL, LDL/HDL, and HDL) from one serum sample assayed 10 times 
within the same analysis. Reproducibility was evaluated by calculating the inter-assay %CV of 
each density region (TRL, LDL/HDL, and HDL) from one serum sample in 10 different runs, 
each on a different day.  
II.2.3 Effects of freeze-thaw cycle  
Blood samples were obtained from 4 healthy dogs. Food was withheld for at least 12 
hours prior to blood collection. Written informed consent was obtained from all owners and the 
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study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of 
Texas A&M University (IACUC2014-0109CA). Blood samples were collected in plain glass 
tubes and left to clot for at least 40 minutes at room temperature. The samples were then 
centrifuged for 15 minutes at 1,600 × g and 20°C. Immediately after the centrifugation, 
lipoprotein profiling was performed as a baseline. The rest of the serum samples were aliquoted 
and stored at -80°C until analysis. The samples were thawed and refrozen up to 3 times, and 
analyzed at each point in the freeze-thaw cycle (1, 2, and 3) within 5 days after the blood 
collection. The %CVs of each density region (TRL, LDL/HDL, and HDL) were calculated 
between the baseline and each freeze-thaw time point.  
II.2.4 Stability of lipoproteins in canine serum samples  
Blood samples were obtained from 3 healthy dogs. The protocol for the blood draw was 
as mentioned above, and the same AUP (IACUC2014-0109CA) was used. Written informed 
consent was obtained from all owners of enrolled dogs. Lipoprotein profiling was performed at 
the same day of the blood collection as a baseline. The rest of the serum samples were aliquoted 
and stored at 4°C, -20°C, and -80°C until analysis. The serum samples stored at 4°C and -20 °C 
were analyzed after 3 days, 1 week, and 1 month. The serum samples stored at -80°C were 
analyzed after 3 days, 1 week, and 1, 3, 5, 6, 8, 9, 10, 11, and 12 months. The %CVs of each 
density region (TRL, LDL/DHL, and HDL) were calculated between the baseline and each time 
point under each storage condition. 
II.2.5 Continuous lipoprotein density profiling (CLPDP) 
The CLPDP was carried out as described previously with some modifications.56,81 
Briefly, 1280 µL of 0.18 M NaBiEDTA density solution (Tokyo Chemical Industry Co., Ltd., 
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Tokyo, Japan) was mixed with 10 µL of serum and 10 µL of NBD C6-ceramide (Cayman 
Chemical Company, Ann Arbor, MI). Then 1150 µL of the mixture was transferred into a 
polycarbonate centrifuge tube (Beckman Coulter, Brea, CA). The sample tubes were centrifuged 
at 867,747 × g  and 4oC for 6 hours in Optima MAX-LP ultracentrifuge (Beckman Coulter, Brea, 
CA) with a fixed angle MLA-130 rotor (Beckman Coulter). After centrifugation, the tubes were 
immediately imaged by a fluorescence imaging system consisting of a digital camera (Quantifire 
XI, Optronics, Muskogee, OK) and a metal halide continuous light source (Dolan-Jenner 
Industries, Boxborough, MA). Following ultracentrifugation, the image of each tube was 
converted to a density profile using a software program, OriginPro7.5 (OriginLab, Northampton, 
MA). The tube coordinate (mm) on the X-axis of the lipoprotein profile corresponded to an 
actual centrifuge tube coordinate (mm). Zero mm indicated the top of the tube, and 33 mm 
indicated the bottom of the tube. The average intensity of fluorescence was plotted on the Y-axis 
to produce a lipoprotein profile. The less dense particles, such as triglyceride-rich lipoproteins 
(TRL), migrated near the top of the tube, whereas more dense particles, such as HDL, settled at 
the bottom of the tube. For statistical analysis, total lipoprotein intensity and fractional intensities 
of each region were determined by measuring the area under the curve (AUC) of the entire 
fluorescence trace and each region, respectively. In addition, each AUC value was normalized by 
the total AUC and presented as AUC%.  
II.2.6 Electron microscopy  
Transmission electron microscopy (TEM) has an advantage of greater resolution of the 
ultrastructure of biological and inorganic specimens. TEM consists of an electron emission 
source, electromagnetic lenses and an electron detector. Unlike light microscopes, electron 
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microscope uses a beam of electrons generated by electron gun to form an image. Magnification 
and focus are obtained by electromagnetic lenses because glass lenses for light microscopes 
would impede electrons. 82,83  
One blood sample was obtained from a healthy dog. The protocol and AUP 
(IACUC2014-0109CA) mentioned above were used for the blood draw. Written informed 
consent was obtained from the owner of the enrolled dog. Food had been withheld from the dog 
for at least 12 hours prior to the blood collection. In addition, a blood sample was obtained from 
a healthy cat. The study protocol was approved by the IACUC of Texas A&M University 
(IACUC2017-0190CA). Food was not withheld for the purpose of this blood collection. The cat 
was fed commercial dry food one hour prior to the blood collection. The blood samples were 
collected in serum tubes without any additives and left at room temperature for at least 40 
minutes. The samples were then centrifuged for 15 minutes at 1,600 × g and 20°C. The serum 
samples were stored at 4°C until analysis. Ten µL of serum sample and 1280 µL of the 
NaBiEDTA density solution were mixed well. The sample solution was centrifuged at 867,747 × 
g  for 6 hours at 4°C. After centrifugation, nominal LDL/HDL and HDL ranges (1.0191-1.0629 
g/mL and 1.0632-1.178 g/mL, respectively) were manually removed from the top of the tube by 
a pipette based on the tube coordinate (mm) corresponding to nominal LDL/HDL and LDL (9.1-
22.7 mm, and 22.7-29.0 mm, respectively). Each fraction was desalted using a 0.15 M sodium 
chloride solution and a centrifugal filter, Amicon® Ultra-0.5mL (MilliporeSigma, Billerica, 
MA). After desalting, the fractions were stored at 4°C until further analysis. Each fraction of 
canine serum was negatively stained by 2% of phosphotungstate and the grids were examined 
with a transmission electron microscope, Philips Morgagni 268 TEM (FEI, Hillsboro, OR). The 
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diameters of 550 particles were measured by an image processing program, ImageJ (public 
domain). 
II.3 Results  
II.3.1 Assay repeatability and reproducibility   
Table 1 presents the %CVs for intra- and inter-assay variability for both AUC and 
AUC% for all 3 density ranges (TRL, LDL/HDL, and LDL). The highest %CV for intra-assay 
variability was 11.2%, while the highest %CV for inter-assay variability was 21.4%.  
 
 
 
 Intra-assay Inter-assay 
 
AUC %CV(AUC%) %CV(AUC) %CV(AUC%) 
TRL  11.2 8.8 21.4 19.8 
LDL/HDL  7.3 3.1 10.6 8.0 
HDL  4.6 0.8 9.3 3.7 
Table 1 %CVs for intra-and inter-assay variability for three density ranges: TRL, nominal 
LDL/HDL, and nominal HDL. AUC=area under the curve; CV= coefficient of variation; HDL= 
high density lipoproteins; LDL= low density lipoproteins; TRL=triglyceride rich lipoproteins  
 
 
 
II.3.2 Effect of freeze-thaw cycles  
For the density range of TRL, the %CVs for the samples thawed up to three times after 
storing at -80°C were relatively high (median [min-max]:  23.7 [2.3-39]%: Table 2). For the 
density range of LDL/HDL, the %CVs for the samples thawed up to three times after storing at -
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80°C were less than 17.7 % (Table 3). For the density range of HDL, the %CVs for the samples 
thawed up to three times after storing at -80°C were less than 6.7% (Table 4).  
 
 
 
          A B C D 
TRL AUC AUC% AUC AUC% AUC AUC% AUC AUC 
-80°, thawedx1 17.7 22.6 2.3 5.2 30.0 31.1 28.7 29.0 
-80°C, thawedx2 23.9 20.6 23.9 22.0 11.0 9.5 24.3 19.4 
-80°C, thawed x3 26.2 27.2 10.5 9.1 39.0 38.1 23.6 26.3 
Table 2 The %CVs for the effect of freeze-thaw cycles for the density range of TRL under different 
storage conditions. A, B, C, and D represent four different serum samples from four healthy dogs. 
 
 
 
          A B C D 
LDL/HDL AUC  AUC% AUC AUC% AUC AUC% AUC AUC% 
-80°C, thawedx1 9.3 2.2 1.9 7.0 13.8 11.4 15.7 15.1 
-80°C, thawedx2  3.4 1.5 6.4 2.3 2.0 2.9 2.8 3.0 
-80°C, thawedx3 1.6 0.9 6.3 3.0 17.7 16.1 15.2 11.6 
Table 3 The %CVs for the effect of freeze-thaw cycles for the density range of nominal LDL/HDL 
under different storage conditions. A, B, C, and D represent four different serum samples from 
four healthy dogs. 
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 A B C D 
HDL AUC  AUC% AUC AUC% AUC AUC% AUC AUC% 
-80°C, thawedx1 6.7 1.1 4.8 3.0 4.3 1.5 0.4 0.7 
-80°C, thawedx2 5.4 0.6 1.6 2.2 3.1 0.7 5.0 0.8 
-80°C, thawedx3 3.5 1.2 2.4 1.2 2.6 1.6 6.5 0.1 
Table 4 The %CV for the effect of freeze-thaw cycles for the density range of nominal HDL under 
different storage conditions. A, B, C, and D represent four different serum samples from four 
healthy dogs. 
 
 
 
II.3.3 Stability of lipoproteins in canine serum samples  
Table 5 and 6 present the %CVs for samples measured at day 0 and at various time points 
after storage at 4°C or -20°C for 3 days, 1 week, and 1 month. The %CVs for the density range 
of TRL were less than 35%, the %CVs for the density range of LDL/HDL were less than 19.5%, 
and the %CVs for the density range of HDL were less than 9.1%. Table 7 presents the %CV for 
samples measured at day 0 and various time points after storing at -80°C for 3 days, 1 week, and 
up to 12 months. Under these conditions, the %CVs for the density ranges of TRL, LDL/HDL, 
and HDL were <24.6%, <13.9%, and <7.7%, respectively.  
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E F G 
%CV(AUC) %CV(AUC%) %CV(AUC) %CV(AUC%) %CV(AUC) %CV(AUC%) 
TRL  14.3 11.7 23.8 20.8 20.1 19.3 
LDL/HDL  8.9 7.0 14.2 10.6 19.5 16.4 
HDL 3.4 3.8 3.3 5.2 5.4 6.0 
Table 5 %CVs for stability of lipoprotein profiles (AUC and AUC%) for samples stored up to 1 
month at 4°C. E, F, and G represent three different serum samples from three different dogs. 
AUC=area under the curve; CV= coefficient of variation; HDL= high density lipoproteins; LDL= 
low density lipoproteins; TRL=triglyceride rich lipoproteins  
 
 
 
 
 
           
 
E F G 
%CV(AUC) %CV(AUC%) %CV(AUC) %CV(AUC%) %CV(AUC) %CV(AUC%) 
TRL 14.1 5.5 6.8 11.5 35.0 31.2 
LDL/HDL 15.2 7.3 4.8 2.5 8.2 7.7 
HDL 9.1 3.7 7.0 1.3 8.7 2.8 
Table 6 %CVs for stability of lipoprotein profiles (AUC and AUC%) for samples stored up to 1 
month at -20°C. E, F, and G represent three different serum samples from three different dogs.  
AUC=area under the curve; CV= coefficient of variation; HDL= high density lipoproteins; LDL= 
low density lipoproteins; TRL=triglyceride rich lipoproteins  
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 E F G 
%CV(AUC) %CV(AUC%) %CV(AUC) %CV(AUC%) %CV(AUC %CV(AUC%) 
TRL 18.5 18.8 16.1 16.0 21.5 24.6 
LDL/HDL 13.9 7.3 11.2 2.5 11.6 7.7 
HDL 7.7 3.5 5.0 3.3 5.9 1.7 
Table 7 %CVs for stability of lipoprotein profiles (AUC and AUC%) for samples stored up to 12 
months at -80°C. E, F, and G represent three different serum samples from three different dogs.  
AUC=area under the curve; CV= coefficient of variation; HDL= high density lipoproteins; LDL= 
low density lipoproteins; TRL=triglyceride rich lipoproteins  
 
 
 
II.3.4 Electron Microscopy  
II.3.4.1 Canine lipoprotein particles  
Electron microscopy examination showed the spherical particles in both density ranges. 
The particles within the density range of LDL/HDL ranged in size from 9.5-29.0 nm (median: 
16.1 nm; Figure 1). The particles within the density range of HDL ranged in size from 9.7-17.2 
nm (median: 13.2 nm; Figure 2). Figure 3-4 presents the distribution of particle diameters. Figure 
3 shows that approximately 52% of particles within the density range of LDL/HDL were 
between 11.0 and 17.0 nm in diameter, while 47% of particles within the same range were 
between 17.0 and 30.0 nm in diameter. Almost all particles within the density range of HDL 
were between 10 and 17.5nm in diameter (Figure 4).  
II.3.4.2 Feline lipoprotein particles   
Electron microscopy examination showed spherical particles in both density ranges. The 
particles within the density range of nominal LDL (1.0191-1.0629 g/mL) ranged in size from 7.6 
to 34.6 nm (median: 12.6 nm; Figure 5 and 6). The particles within the density range of nominal 
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HDL (1.0632-1.178 g/mL) ranged in size from 8.3 to 16.2 nm (median: 9.9 nm; Figure 7 and 8). 
Approximately 83% of lipoproteins within the LDL range were 9-16 nm in diameter, while more 
than 90% of lipoproteins within the HDL range were 9-11 nm in diameter.  
 
 
 
 
Figure 1 Negatively-stained (2% phosphotungstate) canine lipoproteins of the density range of 
nominal LDL (1.0191-1.0629 g/mL). Bar=20nm. 
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Figure 2 Negatively-stained (2% of phosphotungstate) canine lipoproteins of the density range of 
nominal HDL (1.0632-1.178 g/mL). Bar =20 nm. 
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Figure 3 The distribution of diameters (nm) of canine lipoproteins within the density range of 
nominal LDL/HDL (1.0191-1.0629 g/mL).  
 
The diameters of 550 particles from each density range were measured. 
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Figure 4 The distribution of diameters (nm) of canine lipoproteins within the density range of 
nominal LDL/HDL (1.0191-1.0629 g/mL).  
 
The diameters of 550 particles from each density range were measured.  
 
 
 
 
 
 
 
 
 
 
 34 
 
 
 Figure 5 Negatively-stained (2% phosphotungstate) feline lipoproteins of the density range of 
nominal LDL (1.0191-1.0629 g/mL).  
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Figure 6 The distribution of diameters (nm) of feline lipoproteins within the density range of 
nominal LDL (1.0191-1.0629 g/mL). 
 
The diameters of 600 particles from each density range were measured.  
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Figure 7 Negatively-stained (2% phosphotungstate) feline lipoproteins of the density range of 
nominal HDL (1.0632-1.178 g/mL). 
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Figure 8 The distribution of diameters (nm) of feline lipoproteins within the density range of 
nominal HDL (1.0632-1.178 g/mL). 
 
The diameters of 600 particles from each density range were measured.  
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II.4 Discussion  
The CLPDP method was initially developed to analyze lipoprotein profiles in human 
plasma samples based on human lipoprotein density distribution.74  For partial validation of the 
CLPDP technique for use with canine serum samples, we performed intra- and inter- assay 
validation using one pooled canine sample. The intra- and inter- assay variability showed that the 
CLPDP was repeatable and reproducible for the density ranges of nominal LDL/HDL and HDL, 
whereas the method was repeatable but not reproducible for the density range of TRL. A larger 
sample size with range of lipoprotein concentrations (high and low) is needed to fully 
analytically validate the CLPDP. In addition, we evaluated the effect of the freeze-thaw cycles 
on lipoprotein profiling as well as the stability of lipoprotein profiles under different storage 
conditions for different storage time periods. The effect of up to three freeze-thaw cycles after 
storing at -80°C was acceptable for the density ranges of nominal LDL/HDL and HDL. 
However, storing at -80°C may not be suitable for evaluating the density range of TRL and fresh 
samples may be required. We also found that lipoproteins in canine serum which are in the range 
of nominal LDL/HDL and HDL are stable for up to 1 month at 4°C and -20°C as well as for up 
to 12 months when stored at -80°C. These findings suggest that sample handling, storage 
condition, and freeze-thaw cycles in this study did not affect the assessment of lipoprotein 
profiles and were unlikely to affect the results collected from clinical samples.   
Canine HDL and LDL overlap in hydrated density, making it impossible to separate them 
completely based on their density.78,79 Therefore, the lipoprotein classification based on their 
density distribution utilized in human samples does not precisely represent the canine lipoprotein 
distribution. In order to investigate canine lipoprotein distribution by the CLPDP, we examined 
the shapes and sizes of canine lipoproteins in the density ranges of nominal LDL/HDL and HDL 
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with an electron microscope. Negative-staining electron microscopy showed that spherical 
particles in both density ranges. Approximately 52% of particles within the density range of 
nominal LDL/HDL (1.0191-1.0629 g/mL) were between 11.0 and 17.0 nm in diameter, while 
47% of particles within the same range were between 17.0 and 30.0 nm in diameter. Almost all 
particles within the density range of nominal HDL (1.0632-1.1781 g/mL) were between 10 and 
17.5 nm in diameter. These results are similar to the previous reports on human and canine 
lipoprotein diameters.75,78 This finding suggests that there is overlap of particle diameters 
between the two density ranges distributed by the CLPDP, but the density range of LDL showed 
bigger particles, which is one of characteristics of LDL particles.  
Electron microscopic examination also showed that feline lipoproteins were spherical and 
the diameters of the majority of lipoproteins that fell into the LDL density range were larger than 
those that fell into the HDL density range as has also been reported in humans and dogs. 75,78 In 
addition, feline lipoproteins in this study were smaller in diameter than what has previously been 
reported for lipoproteins in humans and dogs.75,78 These findings suggest that the CLPDP 
separates feline lipoproteins well and can be used to evaluate lipoprotein density distributions in 
feline serum samples. We examined serum lipoproteins with TEM only from one healthy cat, 
thus this result might not represent lipoprotein sizes in other healthy cats. A larger sample size is 
needed to further investigate average diameters of feline lipoproteins. 
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CHAPTER III  
ANALYTICAL ASSESSMENT OF SERUM LIPOPROTEIN PROFILES IN HEALTHY 
DOGS AND DOGS WITH EXOCRINE PANCREATIC INSUFFICIENCY 
III.1 Introduction  
Lipoproteins transport lipids in the bloodstream and are often classified based on their 
hydrated density. In humans, these density classes include the intestinally derived chylomicrons, 
hepatically assembled very low density lipoproteins (VLDL), and their lipolytic by-products: 
intermediate density lipoproteins (IDL) and low density lipoproteins (LDL), as well as 
peripherally formed high density lipoproteins (HDL).84 In the human literature, altered 
proportions of lipoprotein classes have been described in certain disease states, such as coronary 
artery disease .8 In veterinary medicine, hyperlipidemia is a general term associated with various 
diseases and can cause clinically relevant complications, such as cutaneous xanthomas,18 liver 
disease,19 cholelithiasis,20 pancreatitis,21 glomerular disease,22 lipemia retinalis, or peripheral 
neuropathy.23 However, limited published reports are available in veterinary medicine regarding 
characteristics of lipoproteins in diseased animals.  
Exocrine pancreatic insufficiency (EPI) is a syndrome caused by the insufficient 
synthesis and secretion of pancreatic enzymes.85,86 The pancreatic enzymes contribute to 
digestion of dietary lipid (e.g., lipase and phospholipase), proteins (e.g., trypsin and 
chymotrypsin), and carbohydrates (amylase), and other macronutrients (e.g., elastase, DNAse 
and RNAse).87 The most common causes of EPI in dogs are acinar atrophy or chronic 
pancreatitis, resulting in an absolute lack of pancreatic acinar cells.85 It has been estimated that 
more than 90% of the functional capacity of the exocrine pancreas must be lost before clinical 
 41 
 
signs develop.86 Clinical signs include weight loss, increased appetite, loose stool, and a poor 
hair coat. EPI is treated with pancreatic enzyme replacement therapy.85,86 Thus, we hypothesized 
that 1) dogs with EPI have dyslipidemia due to the lack of lipase, phospholipase, and cholesterol 
esterase, which are necessary to digest and absorb the ingested fats (triglycerides and 
cholesterol), 2) enzyme replacement therapy in dogs with EPI would improve dyslipidemia.  
The aims of this study was to compare the lipoprotein profiles using the CLPDP, and 
serum cholesterol and triglyceride concentrations between 29 healthy dogs, dogs with EPI that 
had been treated with enzyme supplementation (EPI-T: n=22), and those not yet treated (EPI-
NT: n=6) at the time of the sample collection.  
III.2 Materials and methods  
III.2.1 Healthy dogs 
Surplus serum samples from 29 privately owned dogs whose owners had volunteered 
them for other IACUC approved studies were identified. Written informed consent had been 
obtained from all owners of enrolled dogs. Food had been withheld from these dogs for at least 
12 hours prior to the blood collection. In order to determine the dog’s health status, physical 
examination, a serum chemistry profile and a complete blood count were performed. Originally, 
the blood samples were collected in serum tubes without any additives and left for at least 40 
minutes at room temperature. The samples were then centrifuged for 15 minutes at 1,600 × g and 
20°C. The serum fraction was separated and stored at -80°C until lipoprotein profiling. The 
CLPDP (lipoprotein profiling) was performed within 3 months. 
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III.2.2 Dogs with EPI  
Serum samples were obtained from 28 dogs with EPI that were enrolled in a related 
IACUC approved project. Written informed consent had been obtained from all owners of 
enrolled dogs. EPI was confirmed with serum trypsin-like immunoreactivity (TLI) concentration 
≤ 2.5 µg/L. All enrolled dogs with EPI had serum cobalamin concentrations ≥ 400 ng/L for the 
initial study’s criterion not for this study. Other inclusion criteria included age of more than one 
year, presence of one or more clinical signs of EPI (e.g., polyphagia, weight loss, steatorrhea, 
and/or loose, voluminous, and/or malodorous stools), and no evidence of any additional disease 
processes based on history, physical examination, and laboratory analysis. Food had been 
withheld from these dogs for at least 12 hours prior to the blood collection. Serum samples were 
shipped to the Gastrointestinal Laboratory at Texas A&M University overnight with icepacks. 
Laboratory analysis, including TLI, was performed on the next working day, this meant within 4 
days of collection. Surplus serum samples were aliquoted and stored at -80°C until further 
analysis. Lipoprotein profiles were analyzed using the CLPDP within 3 months. The dogs with 
EPI were categorized into two groups: those already being treated with enzyme supplementation 
(EPI-T: n=22) and those not yet treated (EPI-NT: n=6) at the time of blood sample collection.  
III.2.3 Continuous lipoprotein density profiling (CLPDP) 
The CLPDP was carried out as described previously with some modifications.56,81 
Briefly, 1280 µL of 0.18 M NaBiEDTA density solution (Tokyo Chemical Industry Co., Ltd., 
Tokyo, Japan) was mixed with 10 µL of serum and 10 µL of NBD C6-ceramide (Cayman 
Chemical Company, Ann Arbor, MI). Then 1150 µL of the mixture was transferred into a 
polycarbonate centrifuge tube (Beckman Coulter, Brea, CA). The sample tubes were centrifuged 
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at 867,747 × g and 4oC for 6 hours in Optima MAX-LP ultracentrifuge (Beckman Coulter, Brea, 
CA) with a fixed angle MLA-130 rotor (Beckman Coulter). After centrifugation, the tubes were 
immediately imaged by a fluorescence imaging system consisting of a digital camera (Quantifire 
XI, Optronics, Muskogee, OK) and a metal halide continuous light source (Dolan-Jenner 
Industries, Boxborough, MA). Following ultracentrifugation, the image of each tube was 
converted to a density profile using a software program, OriginPro7.5 (OriginLab, Northampton, 
MA). The tube coordinate (mm) on the X-axis of the lipoprotein profile corresponded to an 
actual centrifuge tube coordinate (mm). Zero mm indicated the top of the tube, and 33 mm 
indicated the bottom of the tube. The average intensity of fluorescence was plotted on the Y-axis 
to produce a lipoprotein profile. The less dense particles, such as triglyceride-rich lipoproteins 
(TRL), migrated near the top of the tube, whereas more dense particles, such as HDL, settled at 
the bottom of the tube. For statistical analysis, total lipoprotein intensity and fractional intensities 
of each region were determined by measuring the area under the curve (AUC) of the entire 
fluorescence trace and each region, respectively. In addition, each AUC value was normalized by 
the total AUC and presented as AUC%.  
II.2.4 Nomenclature  
For statistical analysis, the numbering nomenclature from subfractions #2 to #11 was 
created based on every 2 mm (tube coordinate) from the top of the tube except subfraction #1. 
Subfraction #1 was determined based on the first peak (1.0102-1.0190 g/mL), which corresponds 
to TRL, such as chylomicrons and VLDL. Subfractions between #2 and #8 correspond to 
nominal LDL/HDL (1.0191-1.0629 g/mL), and subfractions between #9 and #11 correspond to 
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nominal HDL (1.0632-1.1781 g/mL). Total lipoprotein intensity was also determined by 
measuring the AUC of entire fluorescence trace and presented as a total AUC.  
III.2.5 Serum triglyceride and cholesterol concentrations  
Serum cholesterol and triglyceride (TG) concentrations were measured using a clinical 
chemistry analyzer (SIRRUS, STANBIO, Boerne, TX). 
III.2.6 Lipoprotein metabolism index  
An index, termed lipoprotein metabolism index was created to aid interpretation of the 
results by calculating the ratio of #10 (AUC%) to #3 (AUC%). Subfraction #3 corresponds to the 
density range of 1.0230-1.0272 g/mL, which corresponds most likely to apoB containing 
lipoprotein particles, such as VLDL and LDL.56 Subfraction #10 corresponds to the density 
range of 1.0858-1.1190 g/mL, which corresponds most likely to apolipoproteinA-I (apoAI) 
containing lipoprotein particles (HDL).56,75 Thus, the lipoprotein metabolism index indicates the 
ratio between VLDL/LDL and HDL.  
III.2.7 Statistics  
The distribution of the data was assessed using the Shapiro-Wilk test and visual 
inspection. A nonparametric test (Wilcoxon rank sum test) and nonparametric comparisons for 
each pair using Wilcoxon method were used. Significance was set at p <0.05. The Benjamini-
Hochberg False Discovery Rate (FDR) was used to calculate adjusted p-value (q-value) for 
multipule comparisons where appropriate. Significance was set at q <0.05. Metabolomic data 
analysis software, MetaboAnalyst 3.088 was used to generate a principal component analysis 
(PCA) plot in order to show the clustering/overlap among lipoprotein profiles based on %AUCs 
of 11 subfractions in healthy dogs, dogs in the EPI-T group, and dogs in the EPI-NT group.  
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III.3 Results  
III.3.1 Study population  
Table 8 shows breed, sex, weight (kg), and age of the enrolled dogs. None of the 
parameters differed significantly between healthy control dogs, dogs in the EPI-T group, or dogs 
in the EPI-NT group.  
 
 
 
  EPI 
signalment Healthy EPI-NT EPI-T 
Pure breed, n (number of breeds)  19 (12) 6 (3) 17 (10) 
Mixed breed, n 9 0 5 
Males, n (neutered) 
             Females, n (spayed)                             
Weight, median (range) kg                                      
12 (8)  
17 (15) 
27.2 (2.7-40.1)               
3(1) 
3 (3) 
24.7 (9.7-29.4) 
8 (5) 
14 (12) 
24.7 (2.7-37.5) 
Age, median (range) year 4 (1-12)         2.7 (1-4) 2.7 (1-14) 
Table 8 Signalment of healthy control dogs, dogs in the EPI-T group, and dogs in the EPI-NT 
group.  
 
EPI=exocrine pancreatic insufficiency; EPI-NT=EPI without enzyme supplementation; EPI-
T=EPI already treated with enzyme supplementation; n=number of dogs   
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III.3.2 Serum TG and cholesterol concentrations  
Serum TG concentrations in healthy control dogs were significantly higher than those in 
dogs in the EPI-NT group (median [min-max]: 53 mg/dL [34-585 mg/dL] vs. 41 mg/dL [24-51 
mg/dL], p=0.0054). Serum cholesterol concentrations in dogs in the EPI-NT group (median 
[min-max]: 123.5 mg/dL [71-160 mg/dL]) were significantly lower than those in the healthy 
control dogs (median [min-max]: 240 mg/dL [129-368 mg/dL], p=0.0004) or dogs in the EPI-T 
group (median [min-max]: 206.5 mg/dL [76-326 mg/dL],  p=0.0127).  
III.3.3 Lipoprotein profiles  
Figures 9, 10, and 11 are overlay graphs for healthy control dogs, dogs in the EPI-T and 
dogs in the EPI-NT groups, respectively. As mentioned above, subfraction #1 corresponds to 
TRL, subfractions between #2 and #8 correspond to nominal LDL/HDL (1.0191-1.0629 g/mL), 
subfractions between #9 and #11 to nominal HDL (1.0632-1.1781 g/mL) .  
Total AUC and the AUCs for subfractions from #1 to #10 differed significantly between 
all three groups (healthy control dogs, dogs in the EPI-T, and dogs in the EPI-NT group; q< 
0.05), while subfraction #11 did not differ significantly between those three groups (q=0.125). 
Of the subfractions from #1 to #10 except #4 and #8, AUCs in healthy dogs were the highest 
followed by dogs in the EPI-T and then dogs in the EPI-NT groups (healthy dogs > EPI-T > EPI-
NT).  The AUC% for 9 subfractions (2-8, 10, and 11) differed significantly between the three 
groups (q < 0.05), while the AUC% for 2 subfractions, 1 and 9, did not differ significantly 
between all three groups (q = 0.148, q = 0.081, respectively). Moreover, the AUC% for 
subfractions from #3 to #8 and #10 significantly differed between healthy dogs and dogs in the 
EPI-NT (q < 0.05), and between dogs in the EPI-T group and dogs in the EPI-NT group (q < 
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0.05), but not between healthy dogs and dogs in the EPI-T group (q < 0.05). The lipoprotein 
metabolism index (ratio of #10/#3; Figure 12) differed significantly between the EPI-T and EPI-
NT groups (p = 0.0173), and between healthy control dogs and the EPI-NT group (p = 0.0041). 
The PCA plot (Figure 13) shows the distribution of each sample based on their similarity of 
lipoprotein profile composition (%AUC for a total of 11 subfractions). Visual separation could 
be seen with a shift from the right upper to bottom left side of the PCA plot that correspond to 
the differences between healthy control dogs, dogs in the EPI-T group, and dogs in the EPI-NT 
group.  
 
 
 
Figure 9 Overlay of lipoprotein profiles from 29 healthy control dogs.  
The X-axis shows the tube coordinate (mm) and the Y-axis displays the fluorescent intensity. Most 
dogs had similar patterns characterized by a high peak at subfraction #10. 
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Figure 10 Overlay of lipoprotein profiles form dogs with EPI treated with enzyme 
supplementation (EPI-T). Some dogs had smaller peaks at subfraction #10 as well as between 
subfractions #4 and #9. 
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Figure 11 Overlay of lipoprotein profiles in dogs with EPI not yet treated (EPI-NT). 
The dogs in this group had smaller peaks over all.  
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Figure 12 Lipoprotein metabolism index (ratio of fraction #10 to #3) between healthy control dogs, 
dogs with EPI treated with enzyme supplementation (EPI-T), and dogs with EPI not yet treated 
(EPI-NT). 
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Figure 13 Principal component analysis (PCA) plot showing the relationship of lipoprotein profiles 
for healthy dogs (Blue) compered to dogs with EPI treated with enzyme supplementation (EPI-T: 
green) and those not yet treated (EPI-NT: red) 
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III. 4 Discussion 
Serum TG concentrations in healthy control dogs were significantly higher than those in 
dogs in the EPI-NT group. Serum cholesterol concentrations in dogs with EPI that were not yet 
treated (EPI-NT) were significantly lower than those in healthy control dogs or dogs with EPI 
that were already treated (EPI-T). The lipoprotein profiles have shown that dogs with EPI in both 
the EPI-NT and EPI-T had significantly lower AUC andAUC% in most lipoprotein subfractions 
compared to healthy control dogs. When we looked at the lipoprotein metabolism index (ratio of 
#10/#3), dogs in the EPI-NT group had a significantly higher ratio than that of dogs in the EPI-T 
group or healthy control dogs. However, the lipoprotein metabolism index did not differ 
significantly between healthy control dogs and dogs in the EPI-T group. These results suggest 
that dogs with EPI have dyslipidemia as well as disproportionate levels of HDL (fraction #10) 
and VLDL (fraction #3) composed of significantly lower VLDL and HDL levels compared to 
healthy control dogs if they are not treated by enzyme supplementation. These findings can be 
also visually observed by comparing Figures 5, 6, and 7. The PCA plot suggests that dogs in the 
EPI-T group had similar lipoprotein profiles to those of healthy control dogs, whereas dogs in the 
EPI-NT group had altered lipoprotein profiles compared to healthy control dogs. However, even 
though these results suggest that enzyme supplementation therapy in dogs with EPI improves 
dietary lipid assimilation, both the lipoprotein profiles and PCA plot indicate that a few dogs 
under treatment had persistently altered lipoprotein profiles. 
There are important lipoprotein metabolism pathways that might be involved in the 
pathogenesis of dyslipidemia in dogs with EPI. In normal physiological condition, dietary TGs 
are incorporated into chylomicrons in the enterocytes and released into the lymph. The main 
function of chylomicrons is to transport dietary TG into peripheral tissues as well as dietary 
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cholesterol to the liver. The chylomicron remnants eventually bind to the LDL receptor (LDL-R) 
and LDL-receptor-related protein (LRP), and are internalized into the hepatocytes. In the present 
study, dogs in the EPI-NT had significantly lower serum TG concentrations and TRL than those 
in healthy dogs. This result suggests that dogs with EPI have decreased serum TG because of 
insufficient absorption of dietary TG if they are not treated with enzyme supplementation. In 
contrast to the absorption process of dietary TG, endogenously synthesized TG and cholesterol 
are secreted within VLDL particles from the liver. VLDL remnants produced by TG hydrolysis 
in peripheral tissues are taken up by the liver and further metabolized by hepatic lipase to 
become LDL.18 Decreased lipoproteins in the density range of VLDL and LDL in dogs with EPI 
might be explained by insufficient de novo fatty acid biosynthesis in the liver because of 
decreased absorption of carbon sources, such as glucose or amino acids from the intestines as 
well as decreased cholesterol ester uptake from chylomicron into the liver. Nascent HDL 
particles are secreted by the liver and small intestine, and acquire phospholipids and free 
cholesterol from peripheral tissues and TRL via phospholipid transfer protein (PLTP) with 
cholesteryl esters that formed via the action of lecithin-cholesterol acyltransferase (LCAT). 
Nascent HDL particles become larger and less dense HDL particles (HDL3 and HDL2). As 
mentioned above, because dogs with EPI had decreased TRL, their HDLs were most likely 
decreased because of insufficient supplies of phospholipids and free cholesterol from TRL.  
The limitations of this study included a small sample size of the EPI-NT group. Enrolling 
additional dogs into the EPI groups would be required to make a more definitive statement 
regarding the efficacy of enzyme replacement therapy for the improvement of dyslipidemia.  
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The CLPDP might be a useful tool for evaluating dyslipidemia in dogs. Long-term 
observational studies are required to assess the relationship between clinical signs and 
lipoprotein profiles after enzyme replacement therapy in dogs with EPI.  
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CHAPTER IV  
IPOPROTEIN PROFILING IN DOG WITH CHRONIC ENTEROPATHY OR HEPATIC 
DISEASE 
IV. 1 Introduction  
In the human literature, altered proportions of lipoprotein classes have been described in 
certain disease states, such as cardiovascular disorders,7 metabolic derangements,89 and 
inflammatory diseases, such as IBD90,91 and systemic lupus erythematosus (SLE).92,93 It has been 
shown that infection and chronic inflammation impair lipoprotein metabolism and cause a 
variety of changes in plasma concentration of lipids and lipoproteins in human patients.92 The 
mechanisms of these alterations are not fully understood. However, several inflammatory 
mediators have been suggested to play a role in the alteration of lipid and lipoprotein 
metabolism. Inflammatory mediators include, but are not limited to, tumor necrosis factor alpha 
(TNF-α), interleukins (IL-1, 2, and 6), and interferon-gamma (IF- γ). It has also been reported 
that in rodents and humans, increased triglyceride (TG) concentrations are induced by multiple 
cytokines, which rapidly stimulate hepatic fatty acid synthesis94,95 and suppress fatty acid 
oxidation.96 The association between dyslipidemia and inflammation has drawn great attention in 
human medicine because hyperlipidemia has been associated with an increased risk of 
atherosclerotic cardiovascular disease (ASCVD). Moreover, the role of hyperlipidemia 
secondary to systemic chronic inflammation resulting in atherosclerosis remains as one of the 
areas of interest in human cardiovascular disease research. On the other hand, in veterinary 
medicine, few studies have been reported regarding dyslipidemia in dogs with inflammation, 
such as lymphoma,28 parvoviral enteritis,30 and leishmaniasis.29 These studies revealed that dogs 
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with these inflammatory or infectious conditions had similar changes on lipoprotein profiles, 
including significantly increased plasma TG and LDL-C concentrations, and decreased HDL 
concentrations. The effects of infection and inflammation on TG metabolism appear to be similar 
in all species, while changes in cholesterol metabolism differ between species. In rodents, serum 
total cholesterol concentrations and hepatic cholesterol synthesis are increased. On the other 
hand, humans and nonhuman primates show either no change or a decrease in serum cholesterol 
and LDL.72 
In addition, clinical studies and anecdotal observations suggest that hyperlipidemia is 
associated with hepatobiliary disease, such as diffuse vacuolar hepatopathy and gallbladder 
mucocele.38 Also, primary hyperlipidemia was found to be associated with increased serum 
hepatic enzyme activities in clinically healthy Miniature Schnauzers.21 
Apolipoproteins are proteins within lipoprotein particles. The main functions of 
apolipoproteins include providing structural components for assembly of lipoprotein particles 
and regulating lipoprotein metabolism.4,5 While apolipoprotein B (apoB) is the main 
apolipoprotein of chylomicrones (apoB48) and LDL particles (apoB100), the main 
apolipoprotein of HDL is apolipoprotein AI (apoAI). ApoAI is synthesized in both the liver and 
the small intestine. While apoB48 is synthesized by enterocytes and secreted in chylomicrons, 
apoB100 is synthesized in hepatocytes and is the sole apolipoprotein in nascent VLDL.4  
Studies have shown that plasma apoB and apoAI concentrations might serve as markers for risk 
of cardiovascular disease and metabolic syndrome in humans.97,98  
Chronic enteropathy (CE) is a general term used in dogs and cats that describes an 
enteropathy that is associated with more than 3 weeks of continuous or intermittent 
gastrointestinal signs, such as diarrhea and/or vomiting.99 The term CE includes diet-responsive, 
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antibiotic-responsive, and steroid-responsive IBD. The pathogenesis of CE is complex and 
multifactorial. Chronic hepatitis is a progressive disease, which is commonly found in dogs. The 
majority of canine chronic hepatitis is idiopathic, but in a subset of patients, excess hepatic 
copper accumulation (i.e., copper-associated chronic hepatitis) can be identified.100 The gold 
standard for the diagnosis of chronic hepatitis is a liver biopsy. Histopathological examination 
shows the presence of bridging fibrosis along with hepatocellular necrosis and inflammation.100 
Portosystemic shunts (PSSs) are vascular anomalies that connect the portal vein to the systemic 
circulation, bypassing the hepatic sinusoids and liver parenchyma.101 PSSs are considered the 
most common hepatobiliary congenital abnormality and are most commonly seen in small/toy-
breed dogs.102,103 In dogs with PSSs, the venous blood bypasses the liver, which results in poor 
hepatic development, insufficient protein synthesis, altered fat and protein metabolism, and 
eventually liver failure. Understanding lipid metabolism and differences in lipoprotein profile 
patterns in dogs with gastrointestinal disease might enhance the understanding of the 
pathogenesis of these diseases and might even serve as a guide to tailor treatment options for 
some patients.  
The hypotheses of this study were 1) dogs with CE or hepatic disease show an altered 
lipoprotein profile as assessed by CLPDP and 2) impaired synthesis of apolipoproteins in either 
the liver or the intestines might be a part of the mechanism of dyslipidemia in diseased subjects. 
Thus, the aims of this study were 1) to compare serum lipoprotein profiles as well as cholesterol, 
triglyceride, and apolipoprotein concentrations between dogs with CE and healthy control dogs  
and 2) to compare serum lipoprotein profiles between dogs with chronic hepatitis, dogs with 
portosystemic shunt (PSS) and healthy control dogs.  
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IV. 2 Materials and methods  
IV. 2.1 Comparison between healthy control dogs and dogs with CE  
IV. 2.1.1 Healthy control dogs  
Surplus serum samples from 29 healthy dogs enrolled in another AUP approved study 
(IACUC 2016-0177 CA) were used. These dogs had no clinical signs or medical treatments 
within 6 weeks prior to study enrollment, and were defined as healthy controls based on physical 
examination, complete blood count, serum chemistry profile and urinalysis. 
Blood samples were collected after food had been withheld for at least 12 hours. The blood 
samples were collected into tubes without an anticoagulant and left at room temperature for at 
least 40 minutes. The samples were then centrifuged for 15 minutes at 1,600 × g and 20°C, and 
sera were removed from the tubes. The CBC and chemistry panel were performed immediately . 
Leftover serum samples were stored at -80°C until lipoprotein profiling.  
IV. 2.1.2 Dogs with CE  
Thirty-eight dogs with CE that had continuous or intermittent gastrointestinal signs, such 
as diarrhea and/or vomiting for more than 3 weeks were enrolled into the study. All dogs with 
CE underwent a diagnostic workup, including clinicopathologic testing (i.e., complete blood 
count, serum chemistry profile, serum concentrations of trypsin-like immunoreactivity, 
cobalamin, folate, and pancreatic lipase immunoreactivity) and abdominal radiography and 
ultrasonography, or gastrointestinal endoscopy. Collection of serum samples was approved AUP 
protocol (IACUC 2015-0069 CA) after withholding food for at least 12 hours. Serum samples 
were shipped overnight to the GI lab with ice packs. The clinicopathologic tests were performed 
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on the same day or within a few days of collection. Surplus serum samples were aliquoted and 
stored at -80°C until further analysis.  
IV. 2.2 Comparison between healthy control dogs and dogs with hepatic diseases  
IV. 2.2.1 Healthy dogs  
Surplus serum samples from 29 healthy dogs enrolled in another AUP approved study 
(IACUC 2012-101) were used. Blood collection was collected as described earlier.  
IV. 2.2.2 Dogs with hepatic disease 
Surplus serum samples from an unrelated study (IACUC 2014-0320) were used for this 
study. Serum samples from 17 dogs with chronic hepatitis, including some with copper-
associated chronic hepatitis and 9 dogs with PSS were identified. Liver biopsy with 
histopathological examination was performed in each dog.  
IV. 2.3 Assessment of lipoprotein profiles  
The CLPDP was performed as described above. For statistical analysis, AUCs for 
nominal TRL, LDL/HDL, and HDL were determined based on the density ranges of d < 1.0190 
g/mL, 1.0191-1.0629 g/mL, and 1.0632-1.1781 g/mL, respectively.  Each AUC value was 
normalized by the total AUC and presented as AUC%.  
IV. 2.4 Apolipoprotein measurements  
Serum apoAI and apoB concentrations of 6 healthy dogs and 7 dogs with CE were 
measured by a commercially available nuclear magnetic resonance (NMR) assay (LabCorp, 
Liposcience). Linear regression of the NMR subclass signal areas against serum lipid and 
apolipoprotein levels measured chemically in a large study population (n=698) provided the 
coefficients to generate NMR-derived concentrations of apoB and apoAI. NMR-derived 
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concentrations of these parameters are highly correlated (r ~ 0.95) with those measured by 
standard methods (Description of New LP4 Algorithm, LabCorp).  
IV. 2.5 Statistical analysis  
The normality distribution of the data was assessed based on a Shapiro-Wilk test and 
visual inspection. A non-parametric test (Wilcoxon rank sum test) was performed for comparison 
of the measured values between diseased dogs and healthy control dogs. A chi-squared test was 
performed to test homogeneity on sex and breeds of the sample population. Significance was set 
at p < 0.05 for all statistical analyses. Metabolomic data analysis software, MetaboAnalyst 3.088 
was used to generate a principal component analysis (PCA) plot in order to show the 
clustering/overlap among lipoprotein profiles based on AUCs of 11 subfractions in healthy 
control dogs, dogs with CH, and dogs with PSS. The 11 subfractions were determined by tube 
coordinate (every 2 mm) from the top of the tube except subfraction #1. Subfraction #1 was 
determined on the first peak, which corresponds to TRL.  
IV. 2.6 Measurement of serum cholesterol and triglyceride concentrations   
Serum cholesterol (Stanbio Cholesterol LiquiColor) and triglyceride (Stanbio 
Triglyceride LiquiColor) concentrations were measured using a clinical chemistry analyzer 
(Stanbio, Sirrus). 
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IV. 3 Results  
IV. 3.1 Healthy dogs vs dogs with CE  
IV. 3.1.1 Study population  
Table 9 summarizes the signalment of the healthy dogs and the dogs with CE. Sexual 
status did not differ significantly between the two groups. Age and breed type (i.e., pure breed 
vs. mix breed) were significantly different between the two groups (p = 0.0105 and p = 0.0038, 
respectively).  
 
 
 
 
Table 9 Signalment of dogs with CE and healthy control dogs. 
 
 
 
IV. 3.1.2 Measurement of serum cholesterol and triglyceride concentrations   
Serum cholesterol concentrations (Figure 14) were significantly different between dogs 
with CE (median [minimum-maximum]: 163 [47-432] mg/dL) and healthy control dogs (median 
[minimum-maximum]: 240 [129-368] mg/dL; p = 0.0010). In the CE group, 26 % of dogs 
(n=10) had serum cholesterol concentrations below the lower limit of the reference interval 
(reference interval: 124-335 mg/dL), while none of the healthy control dogs had cholesterol 
Healthy (n=29) CE (n=38) p-value 
IF 4 0
FS 14 17
IM 1 2
MN 10 19 p = 0.1579
age (yrs) 6.5 [1-12] 7 [0.5-13] p = 0.0105
pure breed 15 32
mix breed 14 6 p = 0.0038
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concentrations below said lower limit of the reference interval. Serum triglyceride concentrations 
(Figure 15) did not differ between dogs with CE (median [minimum-maximum]: 79.5 [22-323] 
mg/dL) and healthy control dogs (median [minimum-maximum]: 53 [34-585] mg/dL; p = 
0.2148).  
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Figure 14 Comparison of serum cholesterol concentrations in dogs with CE and in healthy control 
dogs. The line depicts the median for each group. 
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Figure 15 Comparison of serum triglyceride concentrations in dogs with CE and in healthy control 
dogs. The line depicts the median for each group. 
 
 
 
IV. 3.1.3 Lipoprotein profiles  
Figure 16 and 17 shows overlay graphs from healthy control dogs and dogs with CE, 
respectively. The AUC for TRL did not differ between two groups (p = 0.8395; Figure 18). The 
AUCs for both nominal LDL/HDL and HDL were significantly lower in dogs with CE than in 
healthy control dogs (p = 0.0063 and p < 0.001; Figures 19 and 20, respectively).  
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Figure 16 Overlay graphs from healthy control dogs. 
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Figure 17 Overlay graphs from dogs with CE. 
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Figure 18 AUC for TRL in dogs with CE and in healthy control dogs. The line depicts the 
median for each group. 
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Figure 19 AUC for LDL/HDL in dogs with CE and in healthy control dogs. The line depicts the 
median for each group. 
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Figure 20 AUC for HDL in dogs with CE and in healthy control dogs. The line depicts the median 
for each group. 
 
 
 
IV. 3.1.4 ApoB and apoAI concentrations  
Serum concentrations of apoAI and apoB were measured in 6 healthy dogs and 7 dogs 
with CE. Serum apoB concentrations did not differ between the two groups (p = 0.9430). Serum 
apoAI concentrations of dogs with CE were significantly lower than that in healthy control dogs 
(p = 0.038; Figure 21). Figure 22 shows comparison of overlay graphs between healthy control 
dogs and dogs with CE that were submitted for apolipoprotein measurements.  
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Figure 21 Serum apoAI concentrations in dogs with CE and in healthy control dogs. The line 
depicts the median for each group. 
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Figure 22 Overlay graphs in 6 healthy control dogs (left) and 7 dogs with CE (right). 
 
 
 
IV. 3.2 Healthy dogs vs dogs with hepatic diseases  
IV. 3.2.1 Study population  
Table 10 shows the signalments of healthy control dogs and dogs with CH or PSS. Their 
sexual status did not differ significantly. Age and breeds distributions were significantly different 
among three groups (p < 0.001).  
 
 
 
 
Table 10 Signalments of dogs with CH or PSS and healthy control dogs. 
Healthy (n=29) CH (n=17) PSS (n=9) p-value 
IF 1 2 1
FS 10 8 1
IM 3 2 3
MN 15 5 4 p = 0.3326
age (yrs) 5 [1.5-10] 8 [3-14] 2 [0.5-5] p  < 0.001
pure breed 7 16 1
mix breed 12 1 8 p < 0.001
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IV. 3.2.2 Lipoprotein profiles  
Figure 23, 24, and 25 show overlay graphs from healthy control dogs, dogs with CE, and 
dogs with PSS. Similar lipoprotein profile patterns consisting of a small peak of TRL and a high 
peak of HDL fractions can be seen among healthy control dogs (Figure 23). On the other hand, 
lipoprotein profiles in dogs with CH appeared to have higher LDL/HDL fractions compared with 
healthy control dogs (Figure 24). Lastly, dogs with PSS had much lower levels of LDL/HDL and 
HDL fractions (Figure 25). AUCs for nominal LDL/HDL were significantly different between 
the three groups (p < 0.0001). Post hoc each pair test showed significant differences between 
each pair (Figure 26). AUCs for nominal HDL were significantly different between the three 
groups (p = 0.0005). Dogs with PSS had significantly lower nominal HDL than the healthy 
control dogs or dogs with CH (p = 0.0025 and p = 0.0001, respectively; Figure 27).  
AUCs% for nominal LDL/HDL were also significantly different between the three 
groups (p < 0.0001). AUC% for nominal LDL/HDL in dogs with CE was significantly higher 
than in dogs with PSS or healthy control dogs (p = 0.0018 and p < 0.0001, respectively; Figure 
28). However, AUC% for nominal LDL/HDL between healthy control dogs and dogs with PSS 
did not differ (p = 0.2572). AUCs% for nominal HDL were significantly different between the 
three groups (p < 0.0001). AUC% for nominal HDL in dogs with CE was significantly lower 
than in dogs with PSS or the healthy control dogs (p < 0.0001 and p = 0.0003, respectively; 
Figure 29). AUCs% for nominal HDL did not differ between dogs with PSS and healthy control 
dogs.  
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Figure 23 Overlay graphs for healthy control dogs. 
 
 
 
 
 
Figure 24 Overlay graphs for dogs with chronic hepatitis. 
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Figure 25 Overlay graphs for dogs with portosystemic shunts. 
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Figure 26 Comparison of AUCs for nominal LDL/HDL of healthy control dogs, dogs with CH, 
and dogs with PSS. 
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Figure 27 Comparison of AUCs for nominal HDL of healthy control dogs, dogs with CH, and dogs 
with PSS. 
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Figure 28 Comparison of AUCs% for nominal LDL/HDL of healthy control dogs, dogs with CH, 
and dogs with PSS. 
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Figure 29 Comparison of AUCs% for nominal LDL/HDL of healthy control dogs, dogs with CH, 
and dogs with PSS. 
 
 
 
IV. 3.2.3 PCA plot  
The PCA plot (Figure 30) shows the distribution of each sample based on their similarity 
of lipoprotein profile composition (AUC for a total of 11 subfractions). While there is some 
overlap between healthy control dogs and diseased dogs, dogs with CH clustered toward the left 
side and dogs with PSS toward the right side.  
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Figure 30 PCA plot of lipoprotein profiles in dogs with CH and PSS and in healthy control dogs. 
 
 
 
IV. 4 Discussion   
It has been reported that inflammation and infection cause dyslipidemia in humans and 
veterinary patients. Lipoproteins have important roles in physiological well-being such as 
maintaining cellular membrane structure and function and transporting a great amount of fat-
soluble vitamins in the circulation.91 Thus, altered lipoprotein metabolism can have significant 
physiological impact on affected patients. To the best of our knowledge, there are no published 
reports regarding lipoprotein profiles in dogs with CE, or with liver disorders, such as CH, or 
PSS. Assessment of lipoprotein profiles in patients may help our understanding of the 
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pathogenesis of these diseases, and provide novel therapeutic targets to improve treatment 
outcomes.  
In this study, we showed that serum cholesterol concentrations were significantly 
decreased in dogs with CE compared with healthy control dogs, while serum triglyceride 
concentrations did not differ between the two groups. Dogs with CE had significantly lower 
LDL/HDL and HDL levels compared with healthy control dogs. In addition, NMR analysis 
showed that dogs with CE had significantly lower apoAI concentrations than that in healthy 
control dogs, while apoB concentrations did not differ between the two groups.  
The altered lipoprotein profiles in dogs with CE may be due to malnutrition secondary to 
reduced dietary intake and/or malabsorption. In addition, several inflammatory cytokines have 
been thought to play roles in the alternation of lipid and lipoprotein metabolism. In fact, Buono 
et al. showed that dogs with CE had increased concentrations of IL-2, IL-6, and TNF-α 
compared with healthy control dogs (unpublished data submitted to ACVIM forum 2018).  
Previous studies have shown increased plasma TG concentrations in humans and mice with 
inflammation and infection. In this study, however, serum TG concentrations did not differ 
between dogs with CE and healthy control dogs. Twenty-six percent of dogs with CE in this 
study had serum cholesterol concentrations below the reference interval, while all healthy control 
dogs had cholesterol concentrations within or above the reference interval. Decreased serum 
cholesterol concentrations in dogs with CE were consistent with previous studies in humans. For 
example, children with Crohn disease are reported to have hypocholesterolemia along with 
reduced LDL-C.91  
ApoAI serves as a structural component for HDL particles and constitutes 70% of HDL 
particles.4 It activates LCAT and is also an anti-inflammatory molecule and an antioxidant.104 It 
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was reported that apoAI mRNA expression was detected in both liver and intestine tissues in 
dogs but its expression in the intestine was only 15% of that in the liver.105 Even though apoAI is 
mainly synthesized in the liver, decreased apoAI concentrations in dogs with CE suggest that 
apoAI synthesis in the intestines may be impaired because of mucosal inflammation. The 
reduced apoAI concentrations might have also contributed to decreased HDL levels in dogs with 
CE.  
In addition, dogs with CH had increased nominal LDL/HDL levels resulting in increased 
proportions of nominal LDL/HDL and decreased proportion of nominal HDL (each AUC/total 
AUC). On the other hand, in dogs with PSS, the proportions of nominal LDL/HDL and HDL 
levels did not differ from those in healthy control dogs, while both nominal LDL/HDL and HDL 
levels were significantly decreased compared with healthy control dogs. These results suggest 
that dogs with CH may have either increased production or decreased clearance of less dense 
particles, such as VLDL, LDL, and less dense HDL. On the other hand, dogs with PSS have 
lower production of all lipoproteins due to poor hepatic development. This finding was also 
supported by low serum cholesterol concentrations in these dogs (data not shown).  
The limitations of this study include that not all dogs with CE had histopathologal 
examination confirmation of mucosal inflammation. In addition, we measured serum 
apolipoprotein concentrations in only 6 healthy dogs and 7 dogs with CE. A bigger sample size 
is needed to confirm our findings.  
In conclusion, we have shown that dogs with CE have lower LDL and HDL levels 
compared to healthy dogs. About one third of dogs with CE had serum cholesterol 
concentrations below the reference interval. This observed dyslipidemia might be due to 
inflammatory cytokines and/or impaired synthesis of apoAI in the intestines as well as 
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malnutrition or malassimilation. In addition, nominal LDL/HDL level was increased in dogs with 
CH, while both nominal LDL/HDL and HDL levels were significantly decreased in dogs with 
PSS. Further studies are needed to determine if addressing dyslipidemia could improve the 
management of dogs with gastrointestinal diseases or hepatopathies.  
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CHAPTER V  
ALTERED LIPOPROTEIN PROFILES IN CATS WITH HEPATIC LIPIDOSIS  
V.1 Introduction  
Feline hepatic lipidosis (HL) is the most common hepatobiliary disease in cats and is 
characterized by excessive accumulation of lipid within hepatocytes, leading to intrahepatic 
cholestasis and severe hepatic dysfunction.106 One study in cats with idiopathic HL showed that 
34% of hepatic mass was triglycerides, compared with 1% in healthy control cats. Feline HL is 
classified into two forms: 1) primary idiopathic HL due to anorexia for a prolonged period of 
time without any identified underlying diseases (e.g., decreased food intake secondary to a 
stressful event or nonpalatable food) and 2) secondary HL due to an underlying disease leading 
to anorexia (e.g., diabetes mellitus, pancreatitis or renal failure), which is more common.106 
Although the pathophysiology of feline HL is complex and still incompletely understood, it is 
known that intense adipose tissue lipolysis and alterations in hepatocellular lipid metabolism 
during anorexia play an important role.  
Previous studies have shown increased concentrations of very-low-density lipoproteins 
(VLDL), each lipid component (triglycerides, cholesterol and phospholipids) in VLDL and 
plasma nonesterified fatty acids (NEFAs) in cats with HL compared with healthy cats.107 In 
addition, similarities were reported in the fatty acid composition of both liver and adipose tissues 
in cats with idiopathic HL.108 These results suggest that in cats with HL, assembly of VLDL in 
the liver is enhanced due to excessive mobilization of fatty acids from adipose tissues to the 
liver. That being said, the assessment of lipoprotein profiles may improve our understanding of 
lipid metabolism in cats with HL, and may serve as a guide for tailored nutritional treatment. The 
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methodology in previous studies was a gradient ultracentrifugation (DGU) technique followed 
by the measurement of lipid concentrations (e.g., triglycerides or cholesterol) by enzymatic 
assays. The drawback of this methodology is that the DGU takes 24 hours and requires 
measurements of lipid components. Continuous lipoprotein density profiling (CLPDP) is a novel 
DGU technique, which uses a self-generating density gradient solution, bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA), and a fluorescent probe, NBD C6-ceramide.56,74 
The advantages of this technique are that it requires only one ultracentrifugation, lasting six 
hours, and allows visualization of a continuous distribution of lipoproteins (lipoprotein profile) 
and also quantification of the lipoprotein subfraction masses by calculating the area under the 
curve (AUC).  
The CLPDP was initially developed to analyze human samples. Demacker et al. showed 
that cats and humans have similar lipoprotein density distributions.109 We hypothesized that cats 
with HL would show altered serum lipoprotein profiles using the CLPDP compared with healthy 
control cats due to intensive peripheral lipolysis in adipose tissue and alterations in 
hepatocellular lipid metabolism. The main objective of our study was to compare lipoprotein 
profiles in healthy control cats and cats with HL to examine the disease associated changes in 
their lipid profile. A secondary objective was to examine how the CLPDP separates feline 
lipoproteins by examining the shapes and diameters of the lipoproteins from the resultant 
subfractions with a transmission electron microscope (TEM). 
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V.2 Materials and methods  
V.2.1 Sample population 
Twenty privately owned healthy cats and 23 cats with HL were enrolled into the study. 
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC) 
of Texas A&M University (AUP2012-241) and written informed consent was obtained from all 
owners. Healthy cats had no clinical signs within three months prior to the study enrollment and 
were defined as healthy controls based on physical examination, a serum chemistry profile and 
urinalysis.  
Cats with HL were presented with various conditions and consequent diagnostic workup 
was not standardized. However, diagnosis of feline HL was made based on combination of 
consistent clinical findings (e.g., vomiting, anorexia, weakness, or weight loss), consistent 
laboratory findings (e.g., elevated bilirubin, ALP or ALT), consistent abdominal ultrasound 
findings (e.g., diffusely hyperechoic liver) in absence of hemolysis and extrahepatic bile duct 
obstruction, and the diagnosis of lipid type vacuolation on cytological evaluation of the liver. 
The evaluation of cats for potential underlying disorders was left at the discretion of their 
attending veterinarians. Food was not withheld for the purpose of this study in cats with HL. 
However, most cats were anorexic and had not eaten for about 8 – 12 hours prior to admission 
per owner. The blood samples were collected into tubes without an anticoagulant and left at 
room temperature for at least 40 minutes. The samples were then centrifuged for 15 minutes at 
1,600 × g and 20°C, and sera were removed from the tubes. Serum samples were transported 
with icepacks to the Gastrointestinal Laboratory at Texas A&M University. Serum samples were 
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kept at -80°C until lipoprotein profiling. The CLPDP for both healthy control cats and cats with 
HL was performed within three month of sample collection.  
V.2.2 Measurement of serum cholesterol and triglyceride concentrations   
Serum cholesterol (Stanbio Cholesterol LiquiColor) and triglyceride (Stanbio 
Triglyceride LiquiColor) concentrations were measured using a clinical chemistry analyzer 
(Stanbio, Sirrus).  
V.2.3 Assessment of lipoprotein profiles  
Lipoprotein profiles were assessed using the CLPDP technique.110 In brief, 1,280 µL of 
0.18 M NaBiEDTA density solution (Tokyo Chemical Industry) was mixed with 10 µL of serum 
and 10 µL of NBD C6-ceramide (Cayman Chemical Company). Then 1150 µL of the mixture 
was transferred into a polycarbonate centrifuge tube (Beckman Coulter). The sample tubes were 
centrifuged at 867,747 x g and 4oC for six hours in an ultracentrifuge (Optima MAX-LP, 
Beckman Coulter) with a fixed angle rotor (MLA-130, Beckman Coulter). After centrifugation, 
the tubes were immediately imaged by a fluorescence imaging system consisting of a digital 
camera (Quantifire XI, Optronics) and a metal halide continuous light source (Dolan-Jenner 
Industries). Following ultracentrifugation, the image of each tube was converted to a density 
profile using a software program (OriginPro7.5, OriginLab). The tube coordinate (mm) on the X-
axis of the lipoprotein profile corresponded to an actual centrifuge tube coordinate (mm). Zero 
mm indicated the top of the tube, and 33 mm indicated the bottom of the tube. The average 
intensity of fluorescence was plotted on the Y-axis to produce a lipoprotein profile. The less 
dense particles, such as triglyceride-rich lipoproteins (TRL), migrated near the top of the tube, 
whereas more dense particles, such as HDL, migrated towards the bottom of the tube. The 
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numbering nomenclature was created for statistical analysis. Subfraction #1 (F1) was determined 
based on the first peak (d < 1.0190 g/mL), which corresponds to TRL, such as chylomicrons and 
VLDL. Subfractions #2 (F2) to #11 (F11) were created by measuring the density of the solution 
collect every 2 mm (tube coordinate) from the top of the tube. Total lipoprotein intensity and 
fractional intensities of each region (F1-F11) were determined by measuring the area under the 
curve (AUC) of the entire fluorescence trace and each region (F1-F11), respectively. In addition, 
AUCs for nominal TRL, LDL and HDL were determined based on the density ranges of d < 
1.0190 g/mL, 1.0191-1.0629 g/mL and 1.0632-1.1781 g/mL, respectively.  Each AUC value was 
normalized by the total AUC and presented as AUC%. As a comparison, subfractions between 
#2 (F2) and #8 (F8) correspond to nominal LDL (1.0191-1.0629 g/mL), and subfractions 
between #9 (F9) and #11 (F11) correspond to nominal HDL (1.0632-1.178 g/mL).  
V.2.4 Statistics  
The normality distribution of the data was assessed based on a Shapiro-Wilk test and 
visual inspection. A non-parametric test (Wilcoxon rank sum test) and parametric test (two 
sample t-test) were performed where appropriate. A Chi-Square test was performed to test 
homogeneity on sex and breeds of the sample population. Significance was set at P<0.05. A 
metabolomic data analysis software, MetaboAnalyst 3.088 was used to generate a principal 
component analysis (PCA) plot in order to show the clustering/overlap among lipoprotein 
profiles based on %AUCs of 11 subfractions in healthy control cats and cats with HL. A receiver 
operating characteristic curve (ROC) was used to calculate sensitivity and specificity at the 
optimal cut-off AUC% of a lipoprotein fraction.  
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V.3 Results  
V.3.1 Study population  
Table 11 shows the breed, sexual status and age of the healthy control cats and cats with 
HL. Breeds and sexual status were similar. Age distribution differed significantly between 
healthy cats (mean± standard deviation (SD): 5.3± 2.9) and cats with HL (mean± SD: 7.8± 3.2; 
P=0.011). Underlying diseases were identified in 10 cats with HL and included pancreatitis, 
neoplasia, histoplasmosis, and cardiac disease; no specific underlying disease was identified in 
the other 13 cats.  
 
 
 
 Healthy cats (n=20) Cats with HL (n=23) 
Breeds (n) 
                     DSH                       
                     DMH  
                     DLH  
                     Pure breeds  
        
13 
5 
2 
0 
                                                      
                                                      
13 
2 
3 
5 
Sex  (n)  
                      
                      female spayed  
                      male neutered  
                   
                      
                     9 (45%) 
11 
                    
 
                     12 (52%)  
11 
Age [mean± SD] 5.3± 2.9* 7.8± 3.2* 
Table 11 Signalment of cats with HL and healthy control cats. 
DSH: domestic short haired, DMH: domestic medium haired, DLH: domestic long haired, HL: 
hepatic lipidosis, *P=0.016 
 
 
 
V.3.2 Measurement of serum cholesterol and triglyceride concentrations   
Serum cholesterol concentrations (reference interval: 73-265 g/mL) did not significantly 
differ between healthy cats (mean± SD: 172± 42 g/mL) and cats with HL (mean± SD: 189± 98 
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g/mL; P= 0.46). Also, serum triglyceride concentrations (reference interval: 25-133 g/mL) did 
not significantly differ between healthy cats (median [min-max]: 78 [32-281] g/mL) and cats 
with HL (median [min-max]:102 [38-1300] g/mL; P=0.25).          
V.3.3 Lipoprotein profiles  
Figure 31 and 32 display overlay lipoprotein profiles for healthy control cats and cats 
with HL, respectively. The Figures readily demonstrate that cats with HL have an altered 
lipoprotein profiles when compared with healthy control cats. The PCA plot (Figure 33) shows 
that lipoprotein profiles of healthy control cats cluster closely together, while the lipoprotein 
profiles of cats with HL are divergent from one another and encompass those of healthy control 
cats. Some cats with HL showed lipoprotein profiles similar to the ones observed in healthy 
control cats.  
The AUC% for each fraction from F2 to F7 (1.0188-1.0524 g/mL) in cats with HL was 
significantly higher than those in healthy cats. In contrast, the AUC% for each fraction from F9 
to F11 (1.0654-1.1781 g/mL) in cats with HL were significantly lower than those in healthy 
control cats. Density subfractions were clustered according to traditional density intervals to 
create nominal TRL (d < 1.0190 g/mL), LDL (1.0191-1.0629 g/mL) and HDL (1.0632-1.1781 
g/mL) fraction designations.74,109 The AUC of the nominal TRL fraction did not significantly 
differ between healthy control cats and cats with HL (p = 0.0796). The AUC of nominal LDL 
and total AUC of cats with HL were significantly greater than those of healthy control cats (P< 
0.0001 and 0.0263, respectively). The AUC of nominal HDL in cats with HL was significantly 
lower than that in healthy control cats (p = 0.00911). When each AUC was normalized to the 
total AUC (AUC%), the AUC% of nominal TRL did not significantly differ between healthy 
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control cats and cats with HL (p = 0.2525). However, cats with HL had a significantly greater 
proportion of LDL (AUC%) than healthy control cats (p < 0.0001; Figure 34). Also, the AUC% 
of nominal HDL in cats with HL was significantly lower than healthy control cats (p < 0.0001; 
Figure 35).   
Of 11 subfractions, the AUC% of F6 (1.0374-1.0438 g/mL; Figure 36) distinguished cats 
with HL from healthy control cats at an optimal cut-off of 7.6% with a sensitivity of 87% (95% 
confidence interval [CI], 73-100%), a specificity of 90% (95% CI, 80-100%) and an area under 
ROC curve of 93% (95% CI, 84-99%; Figure 37).   
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Figure 31 Overlay of lipoprotein profiles from 20 healthy control cats. 
 
The X-axis shows the tube coordinate (mm) and the Y-axis displays the fluorescent intensity. 
Most cats had similar patterns characterized by a high peak at subfraction #10.  
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Figure 32 Overlay of lipoprotein profiles from 23 cats with hepatic lipidosis. 
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Figure 33 Principal component analysis (PCA) plot showing the relationship of lipoprotein profiles 
between cats with HL (red) and healthy control cats (green). 
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Figure 34 Comparison of area under the curve (AUC)% for low-density lipoproteins (LDL) 
between cats with hepatic lipidosis (FHL) and healthy control cats. P<0.0001. 
 
 
 
 
 
 
 
 
Figure 35 Comparison of the area under the curve (AUC)% for high-density lipoproteins (HDL) 
between cats with hepatic lipidosis (FHL) and healthy control cats. P<0.0001. 
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Figure 36 Comparison of fraction 6 (F6) between cats with hepatic lipidosis (FHL) and healthy 
control cats. 
 
 
 
 
Figure 37 A receiver operating characteristic curve (ROC) of fraction 6 (F6). 
 
 92 
 
V.4 Discussion   
Although the pathophysiology of feline HL is not completely understood, it has been 
suggested that increased nonesterified fatty acids (NEFAs) mobilized from peripheral tissue due 
to excessive lipolysis play a pivotal role in initiating the alternation in lipoprotein metabolism in 
cats with HL.111 The assessment of lipoprotein profiles in cats with HL might help better 
understand lipid metabolism in cats with HL. In the present study, we successfully used CLPDP 
to demonstrate the marked differences in lipoprotein profiles between healthy control cats and 
cats with HL. The advantages of the CLPDP technique include a shorter centrifugation time (6 
hours) and the ability to immediately visualize lipoprotein density distributions. Moreover, the 
use of a fluorescent probe reduces sample volume requirements and direct imaging of density 
profiles obviates the need for additional chemical measurements. The CLPDP was initially 
developed to analyze lipoprotein density distributions (lipoprotein profile) in human plasma. 
Later, this technique was used to analyze lipoprotein profiles in dogs56 as well as other 
species.76,77 In the present study, electron microscopic examination showed that feline 
lipoproteins were spherical and the diameters of the majority of lipoproteins that fell into the 
LDL density range were larger than those that fell into the HDL density range as has also been 
reported in humans and dogs. 75,78 In addition, feline lipoproteins in this study were smaller in 
diameter than what has previously been reported for lipoproteins in humans and dogs.75,78 These 
findings suggest that the CLPDP separates feline lipoproteins well and can be used to evaluate 
lipoprotein density distributions in feline serum samples.   
  Cats with HL in the present study had significantly higher amounts and proportions of 
LDL compared with healthy control cats, while TRL (VLDL) as well as serum triglyceride 
concentrations did not significantly differ between healthy control cats and cats with HL. It has 
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been proposed that various hormones associated with prolonged anorexia, such as glucagon, 
corticosteroids, adrenocorticotropic hormone, or catecholamines, excessively activate hormone-
sensitive lipase that regulates lipolysis in adipocytes.106 Triacylglycerol in adipocytes is 
hydrolyzed into three molecules of NEFA and one of glycerol. The NEFAs are bound to plasma 
albumin in the circulation and are taken up either by muscle cells for energy production through 
β-oxidation or by the liver for synthesis and/or storage of acylglycerols.5 The glycerol is used to 
synthesize hepatic glucose or triglycerides. In fact, it was reported that cats with HL had 
increased serum NEFA and β-hydroxybutyrate concentrations.107 The finding of an increased 
serum VLDL mass in some studies suggests that even though the liver is able to respond to 
excessive influx of NEFAs by increasing secretion of VLDL, its response may be inadequate to 
prevent hepatic steatosis in some cats; i.e., hepatic TG formation exceeds its secretion through 
the formation of VLDL. VLDL are hydrolyzed to VLDL remnants in peripheral tissues and 
further metabolized by hepatic lipase to become LDL.112 However, in the present study, serum 
triglyceride concentrations and TRL levels did not significantly differ between healthy control 
cats and cats with HL. Non-elevated serum triglyceride concentrations in cats with HL was also 
found in a previous study.113 These findings suggest that the liver might have a limited capacity 
of VLDL secretion when hepatic triglyceride accumulation was excessive in cats with HL.113,114  
The current study also shows that cats with HL have significantly lower serum HDL 
compared with healthy control cats. HDL are assembled with apolipoprotein AI (apoAI).4 Lipid-
poor apoAI is secreted from the liver and intestines, and acquires phospholipids and free 
cholesterol from peripheral tissues and TRL to become mature HDL. This “reverse cholesterol 
transport” process is considered antiatherogenic in humans.8 The mechanism of this decrease in 
the HDL fraction in cats with HL is still unknown. Obesity is one of the predisposing factors for 
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the development of feline HL111 and obesity in humans is often associated with dyslipidemia 
featuring decreased HDL- cholesterol. Hepatic lipase that hydrolyzes triglyceride rich HDL 
shows increased activity in humans with obesity.115 During hydrolysis of HDL mediated by 
hepatic lipase, lipid-poor apoA1 is released from HDL particles. Even though lipid-poor apoAI 
can be used to form HDL particles, it is also cleared by the kidneys.116 Renal ApoAI loss is one 
of the mechanisms that could contribute to the reduced HDL that we observed in cats with HL. 
In addition, apoAI synthesis in the liver might be impaired due to hepatic lipidosis. Further 
studies to assess hepatic lipase activity and urinary apoA1 loss in cats with HL are warranted.  
Measurement of pre-prandial serum cholesterol and triglyceride concentrations is 
currently the standard for diagnosing lipid abnormalities and assessing response to treatment.117 
In the current study, serum triglycerides and cholesterol concentrations were similar in healthy 
control cats and cats with HL, suggesting that both are of limited use for assessing lipid 
metabolism in this disease. Both density distributions (overlay graphs) and PCA plots showed a 
high degree of similarity for healthy control cats. In marked contrast, the profiles of cats with HL 
were divergent from one another and often differed dramatically from those of healthy control 
cats. ROC analysis showed that lipoprotein density fraction #6 (F6; d=1.037-1.043 g/mL) with a 
cut-off value of 7.6% had a sensitivity of 87% and a specificity of 90% for distinguishing  
healthy control cats and cats with HL. Given that serum triglycerides and cholesterol 
concentrations did not differ between healthy control cats and cats with HL in the present study, 
the CLPDP might be useful tool to assess lipid metabolism when HL is suspected.  
There were some limitations in this study. We examined serum lipoproteins with TEM 
only from one healthy cat, thus this result might not represent lipoprotein sizes in other healthy 
cats. A larger sample size is needed to further investigate average diameters of feline 
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lipoproteins. The other limitations of this study include the fact that we were unable to collect 
follow-up samples from the cats with HL. Sequential sampling may provide insight about how 
lipid metabolism changes in response to treatment, and would help to investigate whether the 
lipoprotein profiling result might serve as a prognostic marker for cats with HL. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
Lipids are defined primarily based on their solubility, rather than their chemical 
structures.5 According to this definition, lipids are insoluble in water but soluble in non-aqueous 
solvents. Lipids, which include triglycerides, cholesterol, fatty acids, and phospholipids, are 
necessary to maintain homeostasis. For example, cholesterol is the essential precursor for bile 
acids, corticoid steroids, sex hormones, and vitamin D-derived hormones. Phospholipids are the 
backbone component of cell membranes. Because lipids are insoluble in an aqueous 
environment, they need to be packaged into lipoprotein particles before they can travel in the 
blood stream or cross cell membranes. Lipoproteins are conglomerates of lipids and proteins. In 
humans, lipoproteins are commonly categorized into 5 classes based on their densities: 
chylomicrons, very low density lipoproteins (VLDLs), intermediate-density lipoproteins (IDLs), 
low density lipoproteins (LDLs), and high density lipoproteins (HDLs). Chylomicrons are the 
largest particles and are considered exogenous lipoproteins. The main function of chylomicrons 
is to transport dietary TG from the small intestine to adipose tissue and skeletal/cardiac muscle 
as well as to transport dietary cholesterol to the liver.4 Another important function of 
chylomicrons is to carry fat-soluble vitamins, such as vitamin A, D, E and K.5 The chylomicron 
remnants are taken up by the liver and some vitamins are stored in the adipocytes of the liver. 
The other classes of lipoproteins are considered endogenous lipoproteins.1 VLDLs are secreted 
from the liver in order to export endogenously synthesized triglycerides and to deliver 
triglycerides to adipose and muscle tissue. VLDLs lose triacylglycerol and apolipoproteins, and 
become smaller and denser particles, i.e., LDLs. LDLs mainly transport cholesterol to peripheral 
tissues and the liver. HDLs serve to remove cholesterol from peripheral cells and macrophages, 
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and transport the cholesterol to the liver. This process of “reverse cholesterol transport” is 
considered antiatherogenic in humans.  
Atherosclerotic cardiovascular disease (ASCVD) affects more than one-third of the adult 
human population and accounts for 35% of all US deaths.7 The atherosclerotic process is 
complex but appears to be initiated by the retention of LDL particles. Epidemiological studies 
have shown that increased plasma LDL-C and decreased plasma HDL-C concentrations are 
highly associated with an increased risk of ASCVD.118  The obvious importance of ASCVD in 
the human population has led to extensive research on the subject. Thus, there is a wealth of data 
on lipoprotein metabolism in humans and laboratory animals. Unlike in human medicine, 
hyperlipidemia has been considered a relatively benign condition in dogs and cats. In veterinary 
medicine, measurement of pre-prandial serum cholesterol and triglyceride concentrations is 
currently the standard for diagnosing lipid abnormalities. The clinical usefulness of measurement 
of the plasma cholesterol concentration is limited in dogs and cats, mainly because abnormalities 
in plasma cholesterol concentrations in companion animals are not associated with the same 
complications seen in humans. On the other hand, hypertriglyceridemia has been reported to be a 
risk factor for pancreatitis,35 hepatobiliary disease,36 atherosclerosis,37 systemic xanthomatosis,18 
and ocular diseases in dogs and cats.38,39  Previous studies have described lipoprotein profiles in 
dogs with Leishmaniasis,29 obesity,24,25,119 lymphoma,28 dominance aggression,27 parvoviral 
enteritis,30 and in cats with hepatic lipidosis.113,120 Lipoprotein profiles in these studies included 
serum/plasma concentrations of TG, cholesterol, fatty acids, VLDL-C, LDL-C, and HDL- C. The 
most common technique for the assessment of lipoprotein profiles in these studies is the 
estimation of cholesterol concentrations in LDL and HDL particles by chemical precipitation of 
apoB-containing particles (i.e., LDLs) and the Friedewald calculation method.49 However, 
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lipoproteins are highly heterogeneous particles, and cholesterol concentrations within the 
lipoprotein particles do not necessarily reflect their biological properties.73 Therefore, it is more 
meaningful to evaluate the entire lipoprotein distribution rather than cholesterol concentrations 
within lipoprotein particles.73,74 In addition, it has been reported that the precipitation technique 
is not suitable for canine lipoprotein analysis because of co-precipitation with ApoA-containing 
particles (HDLs).79 Some studies used an ultracentrifugation technique and/or liquid-
chromatography to separate lipoprotein fractions and measured the lipid content, such as TG, 
cholesterol, phospholipid, within these fractions by enzymatic assays. However, these techniques 
are often very time-consuming because they require sequential centrifugation steps and are 
followed by enzymatic assays.  
Continuous lipoprotein density profiling (CLPDP) is a novel DGU technique, which uses 
a self-generating density gradient solution, bismuth sodium ethylenediaminetetraacetic acid 
(NaBiEDTA), and a fluorescent probe, NBD C6-ceramide.56 The advantages of this technique 
are that it requires only one ultracentrifugation step, lasting 6 hours, and it allows the investigator 
to visualize a continuous distribution of lipoproteins (lipoprotein profile) and to estimate the 
concentrations of lipoprotein subfractions by calculating the area under the curve.  
The hypotheses of this study were that 1) CLPDP would be a useful tool for the 
assessment of lipoprotein profiles in dogs and cats, and that 2) dogs and cats with gastrointestinal 
disease or hepatic disease have altered lipoprotein profiles as measured by CLPDP when 
compared to healthy controls.  
Prior to assessing lipoprotein profiles in serum samples, we conducted a partial assay 
validation for use of the methodology with canine serum samples; we also conducted an 
evaluation of the effect of freeze-thaw cycles on canine serum samples, and short- and long- term 
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stability studies on canine serum samples kept under different storage conditions. Our partial 
assay validation shows that the CLPDP was repeatable and reproducible. The effect of up to 
three freeze-thaw cycles after storing at -80°C was acceptable for the density ranges of nominal 
LDL/HDL and HDL. However, storing at -80°C may not be suitable for evaluating the density 
range of TRL and therefore, fresh samples may need to be used. We also found that lipoproteins 
in canine serum that are in the range of nominal LDL/HDL and HDL, are stable for up to 1 
month at 4°C and -20°C as well as for up to 12 months when stored at -80°C. It is important to 
note that the lipoprotein classification used in humans does not accurately represent the canine 
and feline lipoprotein distribution because lipoprotein metabolism varies among species. Thus, in 
order to investigate how the CLPDP separates canine and feline lipoproteins, we examined 
canine and feline lipoprotein particles in the density ranges of nominal LDL/HDL and HDL with 
electron microscopy. Negative-staining electron microscopy showed both canine and feline 
lipoproteins as spherical particles in both density ranges. In canine serum samples, there was an 
overlap of particle diameters between the two density ranges with the density range of LDL 
showing larger particles, which is one of characteristics of LDL particles. On the other hand, in 
feline serum, the majority of lipoproteins within the nominal LDL/HDL range were larger than 
those within the nominal HDL range, and there was much less overlap of particle diameters 
between the two density ranges compared with what has been observed in canine serum. In 
addition, overall feline lipoproteins were smaller in diameter than canine lipoproteins. These 
findings suggest that the CLPDP can be used to evaluate canine and feline lipoprotein profiles. 
However, it is important to note that there is a distinct overlap between the LDL and HDL 
density ranges that have been established for used humans, though less so in feline than in canine 
lipoproteins.  
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Our study showed that lipoprotein profiles in dogs with EPI had significantly lower LDL 
and HDL levels compared to healthy control dogs. Moreover, dogs with EPI that had not yet 
been treated with enzyme supplementation (EPI-NT) had significantly lower lipoprotein levels 
than dogs with EPI that were already being treated with enzyme supplementation (EPI-T). These 
findings can be explained by the pathogenesis of EPI: the lack of digestive enzymes in the small 
intestinal lumen leads to insufficient absorption of dietary TG and cholesterol, which in turn may 
lead to dogs with untreated EPI having insufficient VLDL and LDL. In addition, they may not 
have enough free cholesterol in peripheral tissues and/or TRL to synthesize optimal numbers of 
HDL particles. A previous study showed that dogs with experimentally induced EPI (n=8) had 
elevated serum alanine aminotransferase (ALT), aspartate aminotransferase, and alkaline 
phosphatase activities.121 In addition, histopathological examination of liver specimens revealed 
mild to moderate hepatic lipidosis in all these dogs. Hepatic lipidosis in dogs with EPI may be 
the result of maldigestion, malnutrition, and decreased synthesis of apolipoproteins in the liver. 
In the present study, serum ALT was mildly elevated in dogs with EPI. Whether the dogs with 
EPI in our study had hepatic lipidosis is unknown, but hepatic lipidosis might be attributed to 
altered lipoprotein metabolism in dogs with this disorder Lipoprotein profiles can be used to 
assess lipid metabolism in dogs with EPI. For example, the lipoprotein profile may be a useful 
tool for evaluating dyslipidemia as well as monitoring the efficacy of enzyme supplementation in 
dogs with EPI.  
We also investigated lipoprotein profiles in healthy dogs and dogs with chronic 
enteropathy (CE). Our results showed that AUCs for total lipoproteins, nominal LDL/HDL, and 
nominal HDL in dogs with CE were significantly lower than those in healthy control dogs. 
Serum cholesterol concentrations in dogs with CE were significantly lower than controls. 
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Moreover, 26 % of dogs with CE (n=10) had serum cholesterol concentrations below the lower 
limit of the reference interval (RI: 124-335 mg/dL), while all the healthy control dogs had serum 
cholesterol concentrations within or even above the RI. In addition, serum ApoAI concentrations 
in dogs with CE were significantly lower than in healthy control dogs, while serum ApoB 
concentrations did not differ between the two groups. ApoAI serves as a structural component 
for HDL particles and constitutes 70% of HDL particles.4 It has been reported that ApoAI 
mRNA expression can be detected in both hepatic and intestinal tissues in dogs but its expression 
in the intestine was only 15% of that in the liver.105 Even though ApoAI is mainly synthesized in 
the liver, decreased ApoAI concentrations in dogs with CE suggests that ApoAI synthesis in the 
intestines may be impaired because of mucosal inflammation. The reduced ApoAI 
concentrations might also be contributing to decreased HDL levels in dogs with CE. Altered 
lipoprotein profiles in dogs with CE in this study may be due to reduced lipoprotein lipase 
activity, decreased absorption of ApoAI from the small intestine, decreased synthesis of ApoAI 
in the small intestine and the liver, and malabsorption of dietary fat from the small intestines. 
Our results for HDL level and serum cholesterol concentrations were consistent with the 
previous studies in human patients with IBD. However, human patients with IBD had 
significantly higher LDL-cholesterol concentrations. 
Assessment of lipoprotein profiles in dogs and cats with liver diseases was also 
performed. Dogs with chronic hepatitis (CH) had increased levels of nominal LDL/HDL when 
compared to healthy control dogs, whereas as nominal HDL did not differ. These results suggest 
that dogs with CH may have either an increased synthesis or decreased clearance of less dense 
particles, such as VLDL, LDL, and less dense HDL. On the other hand, dogs with PSS had 
significantly decreased levels of both nominal LDL/HDL and HDL when compared to dogs with 
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CH or healthy control dogs. These results indicate that dogs with PSS produce less of every type 
of lipoprotein due to poor hepatic development. This finding was also supported by low serum 
cholesterol concentrations in these dogs.  
Our study also showed that cats with HL had elevated nominal LDL/HDL levels and 
deceased HDL levels compared to healthy control cats. Importantly, even though lipid metabolism 
in cats with HL is presumed to be altered as part of the disease process, our study showed that 
serum cholesterol and triglyceride concentrations are similar between cats with HL and healthy 
control cats. On the other hand, ROC analysis showed that lipoprotein density fraction #6 (F6; 
d=1.0374-1.0438 g/mL) with a cut-off value of 7.6% had a sensitivity of 87% and a specificity of 
90% for distinguishing  cats with HL from healthy control cats. For a better comparison of the 
clinical usefulness of serum TG and cholesterol concentration and the F6, 25% of cats with HL 
had serum cholesterol concentrations above the upper limit of the reference interval, while this 
value was only 5% for healthy control cats. Also, 33% of cats with HL had serum triglyceride 
concentrations above the upper limit of the reference interval, whereas this analyte was increased 
in  only 15% in healthy control cats. On the other hand, 85% of cats with HL had the F6 above the 
cut-off value of 7.6% compared with only 10% of the control cats. These results support the clinical 
usefulness of the lipoprotein profiling in cats with HL. A definitive diagnosis of feline hepatic 
lipidosis requires cytological and histological confirmation of diffuse hepatocellular triglyceride 
vacuolation. However, cats with severe HL are often substantially compromised and may be at 
risk of anesthetic complications and/or a bleeding diathesis, which complicates acquisition of 
hepatic fine-needle aspirates and biopsies of the liver. In addition, because of the added financial 
burden, clinicians may be hesitant to perform ultrasound-guided needle aspiration. In these cases, 
a lipoprotein profile might help to support a clinical suspicion of HL when paired with other blood 
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tests, such as CBC, measurement of liver enzyme activities (e.g., ALP, ALT and GGT), 
electrolytes, and coagulation tests, especially because lipoprotein profiling is cheaper and less 
invasive compared to ultrasound-guided needle aspiration. In our study, a cat with HL who 
responded to supportive care showed a shift in the altered lipoprotein profile to a normal pattern 
within 2 weeks.  “Normal pattern” was defined by the lipoprotein profiles observed in healthy 
control cats. The clinical signs of this cat correlated well with the improvement of its lipoprotein 
profile, suggesting that this could be used as a tool for monitoring the lipid metabolism in cats with 
HL.  Further studies with a larger sample size are needed to confirm whether normalization of the 
lipoprotein profile is consistently associated with an improvement in clinical signs and 
biochemical parameters.  
Given that lipids are crucial for maintaining homeostasis, dyslipidemia might play a role 
in initiation of complications and poor response to treatment, which may negatively affect 
quality of life in dogs and cats with gastrointestinal and hepatic diseases. For example, it has 
been suggested that HDLs possess anti-inflammatory properties and may play a role in innate 
immunity by regulating the inflammatory response in patients with gram-negative sepsis.122 The 
mechanism of the protective effect of HDLs is complex and not completely understood. 
However, in vivo and in vitro studies have shown that LPS binds to and is neutralized by lipid 
emulsions, chylomicrons, VLDLs, LDLs, HDLs, ApoAI and ApoE, with some authors 
suggesting that HDLs show the most potent binding.95,122,123 In other words, dyslipidemia in 
patients with an infection can be viewed as a physiological protective response to pathogens. In 
fact, a previous study in human sepsis patients showed that non-survivors had significantly lower 
concentrations of cholesterol, TG, HDL, LDL, and ApoAI compared to survivors.124 In addition, 
their results indicated that decreased TG concentrations are associated with a higher mortality in 
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patients with sepsis. As another example, impaired fat absorption from the small intestine 
manifested by decreased serum chylomicron concentrations can lead to vitamin deficiencies. 
Impaired fat absorption from the small intestine might be a result of decreased secretion of bile 
acids or damaged intestinal epithelial cells, which can be caused by inflammation or infection.  
In summary, assessment of lipoprotein profiles in patients with gastrointestinal or liver 
disease may improve our understanding of certain aspects of the pathogenesis of these diseases, 
and may also provide a basis for novel therapeutic approaches. In addition, further studies are 
needed to investigate whether identification and management of dyslipidemia may improve 
outcome and quality of life in dogs and cats with gastrointestinal disease or liver disease.  
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